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ABSTRACT
Prolyl oligopeptidase (POP) is an ancient serine endopeptidase that hydrolyzes proline-
containing peptides at the carboxyl end of the proline residue. POP is able to hydrolyze
small peptides that are shorter than 30-mer. Substrates of POP include peripherally
acting hormones, like angiotensins and vasopressin and also many neuroactive peptides,
like substance P and thyrotropin-releasing hormone. Since many of these peptides are
affecting to the memory and learning functions, these findings have served as a rationale
to develop POP inhibitors as antiamnesic drugs. Furthermore, POP has also been
associated with inositol 1,4,5-triphosphate (IP3) signalling. Despite intensive research
into POP inhibitors, the distribution and physiological role of the POP protein are
poorly known.
In this work, we studied the distribution of the POP protein in mammalian tissues
using immunohistochemistry based on a specific POP antibody, and the POP activity
assay. In the mouse whole-body sections, POP is present in high and equal amounts in
the brain, testis, thymus and kidney. Furthermore, the distribution of the POP protein
differs extensively from the distribution of the POP activity both in the brain and
peripheral tissues, and also from the distribution of POP coding mRNA in the brain.
These findings point to a strict endogenous regulation of POP.
At the cellular level, POP is not cell type specific in the peripheral tissues though in
the rat brain it is present only in the neurons, not in the glial cells. However, in the rat
brain POP can be found both in the inhibitory (GABAergic), excitatory (glutamatergic)
and cholinergic neurons, meaning that there is no neurotransmitter specificity. Most
importantly, POP is preferentially localized in the nuclei of the peripheral cells but
exclusively in the cytoplasm of the brain neurons. Moreover, the spatial association of
POP and its well-characterized substrate, substance P, is poor throughout the brain.
These findings point to role for POP in the cell proliferation/differentiation in the
peripheral tissues and protein modification and trafficking in the brain. However, the
strong colocalization of POP with IP3 receptors in the adult hippocampus supports its
role in the memory and learning functions.
National Library of Medicine Classification: QU 136, QV 38, QV 126, WL 300
Medical Subject Headings: Serine Endopeptidases; Tissue Distribution;
Neurotransmitter Agents; Brain; Neurons; Testis; Thymus Gland; Kidney; Cell
Nucleus; Cytoplasm; Substance P;  Cell Proliferation; Cell Differentiation; Protein
Transport; Inositol 1,4,5-Trisphosphate Receptors; Hippocampus; Memory; Learning;
Immunohistochemistry; Mice; Rat
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6-OHDA 6-hydroxydopamine
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BSA bovine serum albumin
ChAT choline acetyltransferase
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DAPI 4',6-diamidino-2-phenylindole
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LTP/LTD long-term potentiation / depression
MInsPP multiple inositol polyphosphate phosphatase
NEP neutral endopeptidase
NK neurokinin
NK1R neurokinin-1 receptor (substance P receptor)
NMDA N-methyl-D-aspartic acid
PAP I/II pyroglutamyl aminopeptidase I and II
PBS phosphate buffered saline
PPT-A pre-protachykinin-A
POP prolyl oligopeptidase
PVN paraventricular nuclei of hypothalamus
RER rough endoplasmic reticulum
SEM standard error of mean
SON supraoptic nuclei of hypothalamus
SP substance P
TH tyrosine hydroxylase
8TRH thyrotropin-releasing-hormone (thyroliberin)
TRH-R1/R2 thyrotropin-releasing-hormone receptors type 1/2
V1R/ V2R  arginine-vasopressin receptors, type 1 and 2
V1aR/ V1bR arginine-vasopressin type 1 receptor, subtype a and b
VPA valproic acid
ZIP Z-L-prolyl-L-prolinal insensitive Z-Gly-Pro-7-amino-4-methylcoumarin
hydrolyzing peptidase
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1 INTRODUCTION
Prolyl oligopeptidase (POP, EC 3.4.21.26) is an 80 kDa serine protease enzyme
(Rawlings et al. 1994) of ancient origin (Venäläinen et al. 2004). POP preferentially
hydrolyses peptides at the carboxyl side of proline residues and mammalian POP
appears to cleave only peptides shorter than 30 amino acids. POP has been implicated in
the hydrolysis of many bioactive peptides such as angiotensins, neurotensin, arginine-
vasopressin, substance P and thyrotropin releasing hormone (for reviews, see Garcia-
Horsman et al. 2007a, Männistö et al. 2007). Several of these peptides are thought to be
involved in the regulation of memory and learning (Huston et al. 1995).
Alterations in POP enzyme activity in serum and brain tissue have been observed in
aging (Agirregoitia et al. 2003a) and in several pathological conditions, including
psychiatric diseases and Alzheimer’s and Parkinson’s diseases (Maes et al. 1995,
Mantle et al. 1996). Moreover, several studies have recently reported that POP is
involved in inositol 1,4,5-phosphate (IP3) signalling in the brain (Williams et al. 1999,
Schulz et al. 2002, Williams et al. 2002, Harwood et al. 2003, Cheng et al. 2005). An in
vitro study by Cheng et al. (2005) even suggested that the enzyme may be a possible
target of certain mood stabilizing drugs. These findings have served as the rationale for
the development of POP inhibitors. POP inhibitors have been shown to prevent the
amnesic effects of scopolamine in rats (Toide et al. 1995a, Morain et al. 2002), improve
cognition in untreated old rats (Toide et al. 1997) and they have restored declining
neuropeptide levels (Toide et al. 1995b, Toide et al. 1996, Bellemere et al. 2005)
However, the effects of POP inhibitors on neuropeptide levels in the brain are still
controversial (Jalkanen et al. 2007, Männistö et al. 2007).
POP is widely distributed among different organisms, including bacterial and
archeal species (Venäläinen et al. 2004, Garcia-Horsman et al. 2007a). In human and
rat, POP enzyme activities have been found in most tissues (Kato et al. 1980b, Daly et
al. 1985, Fuse et al. 1990, Irazusta et al. 2002) and even body fluids contain some POP-
like activity (Goossens et al. 1996). At the subcellular level, POP is known to be mainly
cytosolic (Dresdner et al. 1982) and Schulz et al. (2005) reported a close association
between POP and cytoskeletal component microtubules in glial and neural cell lines
though POP-like activity has also been detected in membranes (O'Leary et al. 1995).
However, previous studies have been made using enzyme activity measurements and by
determining the mRNA coding POP, but the distribution of POP protein has not been
characterized.
Despite intensive research, the true physiological role of POP is still virtually
unknown. The following review of the literature provides a short summary of properties
14
and the possible physiological role of POP in CNS, peripheral tissues and plasma. The
experimental part of this dissertation focuses on the characterization of the distribution
of the POP protein in the body, particularly in the brain, and the spatial association of
the POP protein with neuronal neurotransmitters and potential targets of POP.
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2 REVIEW OF THE LITERATURE
2.1 Proline
The imino acid, proline, is unique with its structure among amino acids. Its side
chain R-group (-CH2-CH2-CH2) is bonded both amino group and ?-carbon (-CH)
resulting in a cyclic structure (Fig. 1).
Figure 1. Structure of proline
The five-membered cyclic structure of proline prevents the rotation around the ?-
carbon-N bond and therefore, its structure allows only few conformations. Due to its
cyclic nature proline is unlikely to be compatible with ?-helix and furthermore, it lacks
the amide H-atom that is necessary for hydrogen bonding. These characteristics of
proline are crucial for its physiological functions. The presence of proline residues in
the polypeptide precursors reduces the sensitivity of the polypeptide chain to proteolysis
by aminopeptidases and carboxypeptidases limiting the enzymatic modification of the
precursors (Yaron et al. 1993, Cunningham et al. 1997a, Berg et al. 2006). Moreover,
the cis-trans isomerization of proline may alter the function of protein and changes in
prolyl isomerization have been considered as a molecular timer with several biological
processes, such as cell cycle, cell signalling and gene expression (Lu et al. 2007).
2.2 Overview of prolyl oligopeptidase (POP)
Prolyl oligopeptidase (POP, EC 3.4.21.26) was identified first by Walter et al.
(1971) in the human uterus where it was found to cleave oxytocin. POP is an 80 kDa
serine protease enzyme belonging to the family S9 of the SC clan (Rawlings et al.
1994). The closest relatives to POP are dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5),
acylaminoacyl peptidase (ACPH, EC 3.4.19.1) and oligopeptidase B (OB, EC
3.4.21.83) (Rawlings et al. 1994, Venäläinen et al. 2004). The POP family has ancient
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origins and it is widely distributed from bacterial and archaeal species to human, and
only fungi do not contain POP enzyme (Venäläinen et al. 2004).
The POP gene has been cloned from several species, including mouse (Ishino et al.
1998), cows (Yoshimoto et al. 1997), pigs (Rennex et al. 1991) and also from human
brain (Tarrago et al. 2005), human lymphocytes (Vanhoof et al. 1994) and T-cells
(Shirasawa et al. 1994), as well as bacterial sources such as Flavobacterium
meningosepticum (Yoshimoto et al. 1991) and Pyrococcus furiosus (Robinson et al.
1995). POP is located in chromosome 10 B2/B3 in mouse (Kimura et al. 1999) and in
6q22 in human (Goossens et al. 1996). In animal species, POP is 710 amino acids long.
POP has a cylindrical shape with a height of 60 Å and a diameter of 50 Å (Fig. 2). The
peptidase domain is formed by N- and C-termini (residues 1-72 and 428-710)
containing the catalytic triad (Ser554, Asp641, His680). The seven bladed ?-propeller
domain is radially arranged around the central tunnel and is embedded within the
cylinder (Fig. 2). Concerted movements of peptidase and ?-propeller domains are
required for enzyme function as substrate induces an opening at the interface of the two
domains while entering into the active site of POP (Szeltner et al. 2004, Juhasz et al.
2005). The relatively small size of the interface opening presumably prevents large
peptide substrates from entering into the active site.
17
peptidase
?-propeller
Figure 2. The 3D-structure of POP. The ribbon diagram is color-ramped blue to red
from the N to the C terminus (modified from Fülop et al. 1998).
The POP ability of cleaving peptides at the carboxyl side of proline is a rare quality
among peptidases. Proline is unique among amino acids due to its cyclic structure and
most peptidases are unable to cleave peptides at a proline residue. POP hydrolyses the -
Pro-Xaa- bond, where Xaa is any amino acid other than proline, since POP it is not able
to break the -Pro-Pro- bond (Polgar 1994, Cunningham et al. 1998). Several bioactive
neuropeptides, such as substance P (SP), thyrotropin-releasing hormone (TRH),
arginine-vasopressin (AVP), angiotensins I-IV, bradykinin and neurotensin (Table 1),
have been found to be POP substrates (for reviews, see Polgar 1994, Garcia-Horsman et
al. 2007a, Männistö et al. 2007). Many of these neuropeptides are associated with
memory and learning (Huston et al. 1995, Cunningham et al. 1997a) and changes in the
levels of these peptides during aging and degenerative diseases in the brain have been
reported (Hasenohrl et al. 2000, Harrison et al. 2001, Hökfelt et al. 2003). Furthermore,
changes in POP enzyme activity or expression in tissues have been detected during
aging (Agirregoitia et al. 2003a, Rossner et al. 2005) and in various diseases such as
Parkinson's and Alzheimer's disease, suggesting a role for POP in these disorders via the
neuropeptide cleavage (Mantle et al. 1996, Kato et al. 1997, Shinoda et al. 1997).
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Table 1. Potential substrates of POP (modified from Garcia-Horsman et al. 2007a).
Substrate Sequence Type of
evidence*
SP R-P-K-P-Q-Q-F-F-G-L-M A, B, C, D(t), E,
F
TRH pQ-H-P–NH2 A, D(t)
AVP C-Y-F-Q-N–C-P-R-G A, D, E, F(t)
Angiotensin I D-R-V-Y-I-H-P–F-H-L A
Angiotensin II D-R-V-Y-I-H-P–F A, B(t), C, D
Angiotensin III R-V-Y-I-H-P–F A
Angiotensin IV V-Y-I-H-P–F A
Bradykinin R-P–P-G-F-S-P–F-R A, B(t), G
Oxytocin C-Y-I-Q-N–C-P-L-G-NH2 A
?-Endorphin Y-G-G-F-M-T-S-E-K-S-Q-T-P-L-V-T-L-F-K-N-
A-I-I-K-N-A-Y-K-K-G-E
A
Neurotensin pQ-L-Y-E-N-K-P-R-R-P-Y-I-L A
?-MSH S-Y-S-M-E-H–F-R-W-G-K-P-V-NH2 D(t)
?-Casomorphin Y-P–F-P-G-P-I A
LVV-hemorphin-7 L-V–V-Y-P-W-T-Q-R-F C
Morphiceptin Y-P–F-P–NH2 A
Urotensin II D-T-P-D-C–F-W-K-Y-C-V A
Humanin M-A-P-R-G-F-S-C-L-L-L-L-T-S-E-I-D-L-P-V-K-
R-R-A
A
The cleavage bonds are shown in bold.
* A, Digestion by purified POP; B, digestion by tissue crude preparations; C, digestion
sensitive to POP inhibitors by crude tissue preparations; D, modulation of peptide levels
by POP inhibitors in vivo; E, peptide effect potentiated by POP inhibitors in vitro; F,
peptide effect potentiated by POP inhibitors in vivo; G, genetic modulation of POP by
the peptide or analogues; (t) tissue or cell-type dependent.
These findings have served as the rationale for the development of POP inhibitors
in an attempt to discover a novel drug to combat memory and learning disorders, which
would act by modifying the neuropeptide levels in the brain. Several inhibitors have
been developed and characterized in the literature with Z-Pro-prolinal, JTP-4819, ONO-
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1603, SUAM-1221, S17092 and ZTTA being the best characterized inhibitors (Wilk et
al. 1983, Tanaka et al. 1994, Toide et al. 1995a, Katsube et al. 1996, Shishido et al.
1996, Barelli et al. 1999, Männistö et al. 2007, Garcia-Horsman et al. 2007, see also
Table 2). Most of the POP inhibitors are substrate-like compounds that interact with the
three subsites of enzyme's substrate binding site: S1, S2 and S3, in which S1-site is most
likely specific for proline. Therefore most of these substances contain a proline or
proline analogue residues at their P1 and P2 sites. An electrophilic P1 site substituent,
such as aldehyde (in Z-Pro-Prolinal) or hydroxyacetyl (in JTP-4819), forms a covalent
adduct to the serine554-residue in catalytic site being crucial for the inhibitor binding
(Venäläinen 2005).
Z-Pro-Prolinal, JTP-4819, S17092 and ZTTA are the most tested POP inhibitors in
different animal models of memory and learning. Of these, Z-Pro-Prolinal, JTP-4819
and S17092 have been shown to prevent the amnesic effects of scopolamine in rats in a
passive avoidance test, especially with higher doses (> 1 mg/kg) (Yoshimoto et al.
1987, Toide et al. 1995a, Morain et al. 2002). Furthermore, repeated administration of
JTP-4819 improved performance in passive avoidance test and in Morris water maze in
rats after middle cerebral artery occlusion (Shinoda et al. 1996) and enhanced cognition
(Morris water maze) in untreated old rats (Toide et al. 1997). Interestingly, after
scopolamine treatment, single dose (5 mg/kg) of KYP-2047 inhibitor improved
performance in Morris water maze with young rats but not with old (Jalkanen et al.
2006). Repeated administration of ZTTA has also shown memory impairement effects
in passive avoidance test after basal forebrain lesion (Shishido et al. 1998) and some
improvements was observed after a single dose in 3-panel runaway task after cerebral
ischemia (Shishido et al. 1996). Moreover, repeated administration of S17092 have
prevented the cognitive symptoms of Parkinson's model induced by chronic low dose of
MPTP (1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine) in monkeys (Schneider et al.
2002).
In some studies, POP inhibitors have restored declining neuropeptide levels in rat
cerebral cortex and hippocampus, e.g. SP (Toide et al. 1996, Bellemere et al. 2003),
TRH, AVP (Toide et al. 1995b, Toide et al. 1996, Bellemere et al. 2005) and ?-
melanocyte stimulating hormone (?-MSH, Bellemere et al. 2003). Especially these
effects were seen after single dose of inhibitor in young rats. Only in the study of Toide
et al. (1995b), repeated administration of JTP-4819 caused significant increase to the
neuropeptide levels. Moreover, some studies have reported that POP inhibitors have
been able to prevent the generation of ?-amyloid protein in Alzheimer's disease (Kato et
al. 1997, Shinoda et al. 1997). However, the changes in POP activity in the generation
of ?-amyloid are more likely to occur from neuronal damage than from a role for the
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enzyme in ?-amyloid production (Petit et al. 2000, Laitinen et al. 2001, Rossner et al.
2005). Moreover, when critically evaluating the results of POP inhibitor studies, the
effects of POP inhibitors on neuropeptide levels in the brain are less convincing (Table
2) and studies with opposite results have been published (Jalkanen et al. 2007).
Table 2. Effects of POP inhibitors to neuropeptide levels in the brain (modified from
Männistö et al. 2007).
Peptide Compound Rat Dosing Brain area and result Reference
SP JTP-4819 Young Single CTX +, HC + Toide et al. 1996
Aged  Single CTX +, HC 0 Toide et al. 1995b
Aged  Repeated CTX +, HC + Toide et al. 1995b
Young Repeated CTX 0, HC 0 Shinoda et al. 1996
Young Single CTX 0, HC 0, HT 0 Jalkanen et al. 2007
Young Repeated CTX 0, HC 0, HT 0 Jalkanen et al. 2007
S-17092 Young Single STR + Lestage et al. 1998
Young Repeated STR + Lestage et al. 1998
Young Single CTX +, HT + Bellemere et al. 2003
Young Repeated CTX 0, HT 0 Bellemere et al. 2003
KYP-2047 Young Single CTX 0, HC 0, HT 0 Jalkanen et al. 2007
Young Repeated CTX 0, HC 0, HT 0 Jalkanen et al. 2007
TRH JTP-4819 Young Single CTX 0, HC + Toide et al. 1996
Young Repeated CTX +, HC 0 Shinoda et al. 1996
S-17092 Young Single CTX +, AMG 0 Bellemere et al. 2005
Young Repeated CTX +, AMG 0 Bellemere et al. 2005
AVP JTP-4819 Young Single CTX +, HC + Toide et al. 1996
Aged  Single CTX 0, HC 0 Toide et al. 1995b
Aged  Repeated CTX 0, HC 0 Toide et al. 1995b
Young Repeated CTX 0, HC 0 Shinoda et al. 1996
S-17092 Young Single CTX 0, HC + Bellemere et al. 2005
Young Repeated CTX 0, HC 0 Bellemere et al. 2005
?-MSH S-17092 Young Single CTX +, HT + Bellemere et al. 2003
Young Repeated CTX 0, HT 0 Bellemere et al. 2003
AMG, amygdala; CTX, cortex; HC, hippocampus; HT, hypothalamus; STR, striatum;
+, elevation; 0, no change.
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Nevertheless, some additional roles other than direct neuropeptide cleavage have
been proposed for POP. Williams et al. (1999) found that POP may be involved in the
regulation of IP3 signalling. They observed that a mutant Dictyostelium, lacking of POP
gene, was resistant to the effects of lithium. Furthermore, administration of a POP
inhibitor restored lithium induced depletion of IP3 levels in the wild-type Dictyostelium
cells (Williams et al. 1999). Similar results were obtained in mammalian cells by Schulz
et al. (2002) (see section 2.3.2.4 for more detailed description). The mechanism of this
action is still unclear, but POP may be able to regulate the synthesis of IP3 via the
multiple inositol polyphosphate phosphatases (MInsPP) (Williams et al. 2000, Harwood
et al. 2003) or intracellular calcium levels via the short sequence of PEP-19, a
calmodulin binding polypeptide (Brandt et al. 2005). Furthermore, several studies have
suggested that POP and its effects to IP3 levels in the cell may be a common mechanism
for several types of mood stabilizing drugs, such as Li+, valproic acid (VPA) and
carbamazepine (Williams et al. 2002, Harwood et al. 2003, Williams 2005). Recently,
Cheng et al. (2005) even suggested that POP could be the direct target for VPA. These
findings may point to a role for POP in psychiatric disorders. However, subchronic
administration of a POP-inhibitor (JTP-4819) had no significant effects on the IP3 levels
in rat cerebral cortex and hippocampus (Jalkanen et al. 2007).
POP has also been suggested as a potential treatment for celiac disease. Gluten
proteins of wheat, barley and rye evoke inflammation of the small intestine villi in
celiac disease, and these grains contain ?-gliadin which has several immunogenic
peptides that are resistant to gastrointestinal tract proteases (Hausch et al. 2002, Shan et
al. 2002). These peptides are proline-rich and therefore, POP has been suggested as
representing a potential treatment for celiac disease since it could be able to degrade
these immunogenic peptides. In some studies, bacterial and to lesser extent also
mammalian POP have been able to accelerate the cleavage time of these peptides (Piper
et al. 2004, Stepniak et al. 2006, Garcia-Horsman et al. 2007b).
POP has also been associated with several other diseases such as cancer,
inflammation, hypertension and eating disorders based on its enzymatic activity and/or
altered levels of its potential substrates. Furthermore, roles in cell death, cell
proliferation and differentiation have also been proposed (for review, see Brandt et al.
2007). However, despite of these findings, the true physiological importance of POP is
still largely undefined.
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2.3 Possible physiological role of POP and the functions of its proposed substrates
in peripheral tissues and CNS
2.3.1 POP in the peripheral tissues
POP activities have been localized in various organs (Kato et al. 1980a, Kato et al.
1980b, Daly et al. 1985, Fuse et al. 1990, Goossens et al. 1996, Agirregoitia et al. 2005)
establishing that POP is widely present outside the CNS. However, the physiological
role of POP in the peripheral tissues is even more unclear than that of POP in the CNS.
2.3.1.1 The distribution and regulation of POP activity in peripheral tissues
The knowledge of distribution of POP in peripheral tissues is based on enzyme
activity measurements. Enzyme activity measurements have been made using substrates
with a suitable Pro-X-bond where X is a fluorescent compound such as ?-
naphthylamine or 4-methylcoumarin, which is activated after POP cleavage. POP
activities have been measured from peripheral tissues such as the rat skeletal muscle
(Daly et al. 1985, Fuse et al. 1990), testis, liver, kidney, lung, renal cortex, heart and gut
(Kato et al. 1980a, Kato et al. 1980b, Fuse et al. 1990, Goossens et al. 1996,
Agirregoitia et al. 2005). The results of these studies are somewhat controversial (Fig.
3), possibly due to the use of different POP substrates and their concentrations.
Generally, in rat, the highest POP activities have been found in the brain (Kato et al.
1980b, Irazusta et al. 2002, Agirregoitia et al. 2005), but Fuse et al. (1990) found the
highest activities in the kidney. In humans, the highest enzyme activities were found
from cancerous tissues and in healthy samples, from the epithelial cells, renal cortex and
testis (Goossens et al. 1996). However, brain POP activity was not measured in that
study.
In the high-throughput gene expression profiling, the highest levels of human POP
mRNA have been found in the testis and different types of lymphocytes. In contrast to
the enzymatic activity studies, the amount of POP mRNA was approximately equal with
internal organs, such as the liver, lungs and pancreas, and the brain. In the rat, the
uppermost POP mRNA expression was observed from the kidney and endothelial cells
while in the mouse the expression was the highest in the thymus. These results are
suggesting that, in contrast to POP enzyme activity, the highest amount of POP mRNA
are not located in the brain tissue (Genomics Institute of the Novartis Research
Foundation (GNF) SymAtlas, Su et al. 2002).
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Interestingly, in nonneural cell lines, POP activity has also been detected from the
nucleus (Ishino et al. 1998) although POP is mainly a cytosolic enzyme (Dresdner et al.
1982). Furthermore, in Sarcophaga peregrina (flesh fly), POP has been detected widely
in the tissues, both in cytoplasm and nucleus (Ohtsuki et al. 1997a, Ohtsuki et al.
1997b). A more detailed discussion of this nuclear POP and its functions is provided in
section 2.3.1.3.
An endogenous POP inhibitor has been described in several studies (Yoshimoto et
al. 1982, Salers 1994, Yamakawa et al. 1994). It was originally found and purified from
the rat pancreas (Yoshimoto et al. 1982) and a pancreatic cell line (Salers 1994) and
thereafter identified also from the regenerating rat liver (Yamakawa et al. 1994). This
substance is a 6.5 kDa POP specific inhibitor (Ki value 2.6 µM) and it is localized
within the cytosolic compartment (Soeda et al. 1985, Salers 1994). However, this
compound has been biologically rather poorly characterized and its regulation and
functions are still obscure.  From other interfering endogenous substances, estradiol-
17?, progesterone (Ohta et al. 1992) and cortisol (Yasuda et al. 1992) are able to
increase POP activity in the peripheral tissues.
Figure 3. Distribution of enzyme activity of POP in the rat in studies by Agirregoitia et
al. (2005), Irazusta et al. (2002), Fuse et al. (1990) and Daly et al. (1985). In order to
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compare the results, enzymatic activity of the brain has been set as 100 % and other
organs are compared to that value.
2.3.1.2 POP and its proposed substrates in peripheral tissues
POP has been implicated in the hydrolysis of various neuropeptides in the CNS
(Table 1) that are also present as transmitters in the peripheral tissues. This review of
the literature below is focused only to SP, TRH and AVP since they have been the best
characterized, also in the POP inhibitor studies.
SP
SP has been widely studied after its discovery in the 1930s (for reviews, see
Leeman et al. 1974, Leeman 1980, Raffa 1998, Harrison et al. 2001, Severini et al.
2002, Hökfelt et al. 2003, Almeida et al. 2004). The amino acid structure of SP (H-Arg-
Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) was first identified by Chang et al.
(1971) in the bovine hypothalamus. There are two potential cleavage sites for POP; Pro-
Lys and Pro-Gln, of which the latter bond has been determined as being the main target
for POP (Kato et al. 1980a, Yoshimoto et al. 1981). Mammalian SP derives from the
pre-protachykinin-A (PPT-A) gene whose gene transcript produces three mRNAs (?-
PPT-A, ?-PPT-A and ?PPT-A) that all encode for SP as well as other tachykinins
(Carter et al. 1990). SP, and these other neuropeptides, are synthesised in the ribosomes
and confined in the perikaryon. Thereafter, SP is packed into vesicles and axonally
transported to the terminal endings for final enzymatic processing (Harrison et al. 2001,
Hökfelt et al. 2003). SP is preferentially released from the synapse, not only in nerve
endings but also from dendrites and the soma, under burst or high frequency firing, and
it is metabolized by extracellular peptidases (Hökfelt et al. 2003). It is known that
several peptidases are involved in the metabolism of SP. In addition to POP, also
neutral endopeptidase (NEP, EC 3.4.24.11), SP-degrading enzyme (SP-DE, EC 3.4.24),
angiotensin-converting enzyme (ACE, EC 3.4.15.1), dipeptidyl aminopeptide IV
(DPIV, EC 3.4.14.5) and cathepsin D (EC 3.4.3.24) and E (EC 3.4.23.34) can degrade
SP. NEP and ACE are thought to be the most important metabolizing enzymes of SP
(Harrison et al. 2001).
SP is able to activate all tachykinin (neurokinin, NK) receptors – NK1, NK2 and
NK2 – but its affinity is highest to the NK1 –receptor (NK1R, Harrison et al. 2001,
Almeida et al. 2004). NK1R is a G-protein coupled receptor and its activation leads to
intracellular IP3 turnover with a resulting elevation of the intracellular calcium level
(Almeida et al. 2004). It should be noted that POP is also implicated in the regulation of
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IP3 and calcium-signalling (see section 2.3.2.4), possibly through a regulation of IP3
synthesis (Harwood et al. 2003).
SP and its receptors, NK1, NK2 and NK3 are distributed widely in peripheral
tissues. SP-immunoreactive neurons projecting from sensory spinal ganglia have their
terminals in the skin (epidermis, blood vessels and hair follicles or glands in the
dermis), joints, submucosa and myenteric plexuses of gastrointestinal (GI) tract,
respiratory tract, endothelial cells of blood vessels, genouritary tract and immune
system (lymph nodes, spleen and thymus). SP has also been detected in smooth muscle,
carcinoid tumors, cromaffin and acidophil cells and bones (for reviews, see Ribeiro-da-
Silva et al. 2000, Harrison et al. 2001, Severini et al. 2002, Liu et al. 2007).
Furthermore, NK1Rs of SP are widely present in the same organs (Quartara et al. 1998).
Interestingly, the distribution of SP and NK1R follows only partially the distribution of
POP enzyme activity in the peripheral tissues. Moderate POP activities have been
measured from the GI tract (Fuse et al. 1990), lungs (Daly et al. 1985, Irazusta et al.
2002, Agirregoitia et al. 2005) and from spleen and lymphoid cells (Goossens et al.
1996). However, accurate and quantative determinations of POP locations in peripheral
tissues have not been reported and therefore, spatial comparison of these substances is
difficult.
The physiological responses of SP in the peripheral tissues are mediated via SP
release from the peripheral endings of capsaicin-sensitive primary sensory neurons.
Several substances and transmitters can affect the release of SP in both inhibitory (i.e.
opiates, 5-HT agonists) or excitatory (i.e. bradykinin, prostaglandins, eicosanoids)
directions. The binding of SP to the NK1R activates the phospholipase C (PLC)
mediated IP3-turnover leading to an increase in the intracellular level of Ca
2+ (Harrison
et al. 2001, Severini et al. 2002).
In the cardiovasculature, SP induces cGMP accumulation and activates Ca2+-
dependent nitric oxide (NO) synthesis in the endothelial cells of blood vessels, and
therefore evokes vasodilatation and plasma extravasation (Quartara et al. 1998, Walsh et
al. 2006), this latter effect being important in neurogenic inflammation (Harrison et al.
2001). The respiratory effects of SP are mediated through the dense NK1 (and partially
NK2) receptor populations in the smooth muscle of bronchus. SP may induce
bronchoconstriction or in some cases, bronchodilatation via NK1R mediated NO release
in the endothelial cells. Moreover, the SP stimulated inflammatory response may be
crucial in the hyperresponsiveness of asthma, and NK1R mRNA is increased in the
respiratory smooth muscle cells of asthmatic subjects (Quartara et al. 1998, Harrison et
al. 2001). In the gut, SP can affect both motility and secretion. The motility functions
are excitatory, though some differences between species do exist (Harrison et al. 2001,
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Severini et al. 2002). Moreover, intra-arterial infusion of SP increases the intestinal
secretion of water and electrolytes and pancreatic juice (Severini et al. 2002). Even
though these effects are mediated mainly via the NK2 receptors, and only to a minor
extent via the NK1R, it has been found that NK1Rs are upregulated during
inflammatory gut diseases, such as Crohn's disease, pseudomembranous colitis
(Ribeiro-da-Silva et al. 2000, Harrison et al. 2001, Almeida et al. 2004) and pancreatis
(Harrison et al. 2001), which have been interpreted as evidence for the inflammatory
functions of SP.  Furthermore, SP rich nerve fibres have been found in suburothelial
layer and smooth muscle layer of the renal pelvis and ureter (Harrison et al. 2001). An
i.v. infusion of SP increases the motility of the genitourinary tract and also causes
plasma extravasation (Harrison et al. 2001, Severini et al. 2002).
SP may also be associated with the immune system, since it is abudantly present in
various immune system organs and cell types. Its proposed participation in
inflammation is supporting this association. It is known that SP induces B- and T-cell
proliferation, immunoglobulin secretion, cellular chemotaxis, and lymphocyte migration
both in vitro and in vivo. However, the mechanism of these actions has remained
unclear (Quartara et al. 1998, Harrison et al. 2001, Severini et al. 2002). Furthermore,
several studies (for review, see Liu et al. 2007) have linked SP to bone metabolism
since SP can increase the proliferation and resorption of bones by an action on bone
marrow.
Although there is a lack of studies concerning the involvement of POP in the SP
hydrolysis in the peripheral tissues, some studies have reported higher POP activity in
rheumatoid arthritis (Kamori et al. 1991) as well as in Mycobacterium tuberculosis-
induced inflammation (Kakegawa et al. 2004). Furthermore, the activity and expression
of POP in the lymphocytes and T-cells (Shirasawa et al. 1994, Vanhoof et al. 1994,
Goossens et al. 1996) may link it to SP.
TRH
TRH was first found and characterized by Boler et al. (1969). Its tripeptidic
structure (pyro-Glu-His-Pro-NH2) contains the Pro-NH2 bond that can be degraded by
POP (Table 1). TRH is derived from TRH-precursor (pro-TRH) which is also a source
of several other neuropeptides closely related to TRH but with different functions (for
review, see Nillni et al. 1999). Pro-TRH is synthesized in the ribosomes and thereafter
processed in the trans-Golgi-network before transportation to the immature secretory
granules. Cleavage of the precursor to active TRH occurs by the action of prohormone
convertases (PC1 and 2) and carboxypeptidase E (Cruz et al. 1996, Nillni et al. 1999).
27
TRH is metabolized extracellularly by pyroglutamyl aminopeptidase I and II (PAP I and
II), thyroliberinase and POP (Nillni et al. 1999).
TRH has two known receptors, TRH-R1 and TRH-R2. These receptors belong to
the G-protein-coupled receptor superfamily and their activation leads to the activation
of calcium-dependent protein kinase via IP3 turnover and/or to the activation PKC and
MAPK, which can induce gene transcription via three transcription factors i.e. cAMP
response element-binding (CREB), AP-1 and Elk-1. Actions of TRH-R1 and TRH-R2
are rather similar, but the activation of the transcription factors seems to be dominate in
the TRH-R2 expressing cells (for review, see Sun et al. 2003). TRH-immunoreactivity
and TRH-receptors (both type 1 and 2, TRH-R1/R2) are present in various organs. Cao
et al. (1998) determined TRH-R1 from rat heart, spleen, liver, lung, skeletal muscle,
kidney and testis using northern blot. Moreover, immunoreactive TRH-R1 and TRH-R2
was found extensively in rat GI tract (Auerbach's nervous branch, Meissner's nervous
branch and mucosa of the stomach), testis and retina, while in adrenal medulla only
TRH-R1 immunoreactivity was seen (Mitsuma et al. 1995, Mitsuma et al. 1999).
Intense expression of TRH is also present in the pancreas, where TRH is synthesized in
the insulin-producing ?-cells (Leduque et al. 1989).
Even though TRH has receptors in various internal non-neuronal tissues, its
peripheral functions are not well understood and even many of its peripheral actions are
mediated via the CNS and the autonomic nervous system. The most important effect of
TRH to peripheral tissues is its indirect involvement to the functions of thyroid gland.
However, since this action is mediated via thyroid-stimulating hormone (TSH), it will
be not discussed in this text. Similar to SP, TRH can also affect the GI-tract.
Intracerebroventricular injections of TRH induce gastric acid secretion, gastric
emptying and intestine motility in rats and rabbits, pointing to a role for central TRH in
the vagal stimulation of GI motility. The abundant presence of TRH receptors in the GI-
tract is also and indication that there may be peripheral release of TRH, but central TRH
is far more potent than i.v. TRH in inducing GI effects (Nillni et al. 1999, Fujimiya et
al. 2000, Beglinger et al. 2002). Moreover, TRH inhibits food and water intake but this
function is regulated via the hypothalamus (for review, see Nillni et al. 1999). The
cardiovascular effects of TRH have also been studied. TRH can modulate cardiac
contractility as an autocrine regulator in a concentration-dependent manner (Socci et al.
1996) and i.v. administration of TRH to rats with ischemic cardiomyopathy evokes an
increase in heart rate, arterial pressure and cardiac output via the regulation of
autonomic nervous system (Jin et al. 2004). In the respiratory system, TRH is able to
raise the respiratory level at high doses. However, even though TRH receptors are
distributed in the lungs, the respiratory control of TRH is mostly mediated via the
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respiratory motoneurons in the medulla (Nillni et al. 1999). The most important
paracrinal effects of TRH occur in the pancreas, where TRH and insulin secretions are
inversely related (Ebiou et al. 1992), i.e. TRH inhibits pancreas secretion and enhances
arginine-stimulated glucagon release (Fragner et al. 1997). Furthermore, high levels of
TRH are present in the genitourinary tract, and TRH may act as a paracrinal regulator in
the reproductive system (Nillni et al. 1999).
The association of POP with the peripheral functions of TRH has been seldom
studied. High POP activity is present in the porcine pancreas (Yoshimoto et al. 1982)
and in the rat pancreatic cell lines (Salers 1994), though Fuse et al. (1990) failed to
detect any POP in rat pancreatic homogenates. The possible involvement of POP in
controlling the level of pancreatic TRH in rats during the development has been studied
by Salers et al. (1992). Even though POP degraded TRH in vitro, it did not hydrolyze
TRH in vivo, evidence that the pancreatic TRH content appears to be principally
regulated during the biosynthetic steps.
AVP
AVP, also known as antidiuretic hormone, was one of the first neuropeptides
recognized, being first described in 1895. It is primarily known as the key regulator of
water and electrolyte balance (for reviews, see Bisset et al. 1988, Rose et al. 2002,
LeJemtel et al. 2007, Rinaman 2007, Caldwell et al. 2008). AVP's amino acid structure,
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2, can be cleaved by POP at the Pro-Arg
bond (Table 2), and it was also one of the first peptides to be confirmed as being
degraded by POP (Walter 1976). Although most of the AVP neurons are located in the
brain supraoptic and paraventricular nuclei (SON and PVN) of hypothalamus, AVP
receptors are also extensively distributed in peripheral tissues, pointing to various
physiological roles for this peptide. AVP has two main receptor types, V1R and V2R, of
which V1R is divided into two subtypes, V1aR and V1bR (or V3R). V1aR are mostly
found in the liver, kidney, adrenal cortex, blood vessels, platelets, lymphocytes and
monocytes and blood vessels (for reviews, see Lee et al. 2003, Caldwell et al. 2008),
while the V1bR mRNA is found in the kidney, thymus, heart, lung, spleen, uterus, and
breast (Lolait et al. 1995). The most well known peripheral AVP receptor is V2, which
is present in the surface of the principle cells of the collecting tubules of kidney,
regulating water reabsorption (Phillips et al. 1990, Lolait et al. 1995, Birnbaumer 2000,
Lee et al. 2003, Caldwell et al. 2008). Even though AVP is found in most peripheral
tissues, its functions are relatively unknown, with the exception of its well known role
in the kidneys and vascular smooth muscles.
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The most important peripheral action of AVP is the regulation of water
reabsorption. Changes in plasma osmolality are detected by hypothalamic
osmoreceptors and activation of these neurons releases AVP into the circulation from
the axon terminals of posterior pituitary. The binding of AVP to the V2 receptors in the
collecting tubules of kidney activates Gs protein mediated cAMP synthesis, and the
synthesis of aquaporin-2 (AQ2) water channel proteins, which shuttle to the apical
surface of collecting duct, allowing free water to pass across the apical membrane (for
reviews, see Birnbaumer 2000, Lee et al. 2003).
The vascular effects of AVP are mediated via the V1bR subtype. AVP release is
stimulated via the cardiopulmonary and sinoaortic baroreceptors, which detect
reductions in blood pressure, especially during dehydration, intense hypotension or
shock. The release of AVP is accompanied by the activation of the renin-angiotensin
system. The binding of AVP to V1bR of the vascular smooth muscle activates the Gq
protein mediated IP3 second messenger system, resulting in the release of intracellular
Ca2+ and arterial vasoconstriction (for reviews, see Schrier et al. 1993, Lee et al. 2003).
Furthermore, the hypothalamic AVP release is associated with liver growth and
increased bile flow after partial hepatectomy, through the V1aR (Nicou et al. 2003).
Furthermore, in the liver, AVP has been linked to the glycogen homeostasis, since it is
able to modify glycogen phosphorylase activity (Kirk et al. 1979). Also V1aR knock-out
mice exhibit major deficiencies in glucose homeostasis (Aoyagi et al. 2007). Within the
blood cells, AVP can cause platelet aggregation and the coagulation of monocytes and
lymphocytes (Inaba et al. 1988).
The effects of POP on peripheral AVP has been poorly studied, but interestingly,
the activity of POP is decreased in atria and increased in ventricles as a consequence of
hypertension such as that seen in left renal artery obstructed rats with nephrectomy
(Cicilini et al. 1994). However, it is not known how the resulting hypertension affects
AVP and whether there is a correlation between POP activity and the effects of AVP on
kidney/blood vessels. Furthermore, renal hypertensive patients displayed a significant
correlation between the POP and ACE activities in serum (Goossens et al. 1996).
Nevertheless, this action of POP may be partially mediated by the hydrolysis of
angiotensins I and II to angiotensin (Garcia-Horsman et al. 2007a)  and the true nature
of serum POP activity is unclear (see chapter 2.3.3).
2.3.1.3 The role of POP in cell proliferation and differentiation
POP has been implicated in several studies to cell proliferation and differentiation
in vitro and even in vivo after POP was found localized in the nuclei of nonneural cell
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lines (Ishino et al. 1998) and in the Sarcophaga peregrina (fresh fly). Ohtsuki et al.
(Ohtsuki et al. 1994, Ohtsuki et al. 1997b) postulated that POP may have a crucial role
in cell differentiation since ZTTA, a specific POP inhibitor, prevented differentiation of
the imaginal discs of Sarcophaga peregrina (fresh fly). They also found that ZTTA
inhibited DNA synthesis, and therefore cell proliferation, in a Sarcophaga cell line
(Ohtsuki et al. 1997a). Similar results have been obtained with the mouse Swiss 3T3
cell line (Ishino et al. 1998).
POP activity in several rat organs is also high during embryonic and early
development stages and this activity becomes reduced in adulthood (Fuse et al. 1990,
Matsubara et al. 1998, Agirregoitia et al. 2003a, Agirregoitia et al. 2007). Kimura et al.
(2002) observed changes in the localization of POP mRNA during sexual maturation in
mouse testis, suggesting that POP may be involved in meiosis and maturation of
spermatozoa. Furthermore, high POP activity in the cancerous tissues (Goossens et al.
1996) may reflect to a role for this enzyme in cell division and/or differentiation.
The mechanism of how POP can modulate DNA synthesis and/or cell
differentiation has remained unknown. Possible substrate for POP participating to these
functions has not been identified. Interestingly, Ikura et al. (2008) recently found that
POP may act similarly to the peptidyl-prolyl isomerases (PPIase) and accelerate the
change of prolyl cis-trans isomerization. These workers studied the isomerization of the
Ala-Pro-bond in N-succinyl-Ala-Ala-Pro-Phe-4-methylcoumaryl-7-amide (AAPF-
MCA) and observed that POP was able to catalyse this reaction with moderate activity
although at a slow catalytic rate when compared to the other PPIases in the same study.
However, changes in the prolyl cis-trans isomerization may lead to different actions of
the same protein, the conformation changes are associated with several functions in
molecular timing, involving the cell cycle, cell signalling, gene expression, immune
response and neuronal functions (Lu et al. 2007). This may offer novel physiological
roles for POP and explain the involvement of POP in the cell cycle and proliferation.
However, more studies clarifying the role of POP in the DNA synthesis/cell
proliferation are needed.
2.3.2 POP in the CNS
POP has been studied most intensively in the brain. In enzyme activity
measurements, the highest activities have been generally found in the brain, especially
in the cerebral cortex where bioactive neuropeptides, such as SP, TRH and AVP are
partially located (Kato et al. 1980b, Daly et al. 1985, Irazusta et al. 2002, Agirregoitia et
al. 2005). Moreover, the basis of POP inhibitor development was to generate a novel
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drug which would prevent the metabolism of bioactive neuropeptides in the brain (Kato
et al. 1980a, Cunningham et al. 1997a). These findings have raised the preconception
that POP must have an important physiological function in the brain.
2.3.2.1 POP enzyme activity and mRNA distribution in the brain
POP enzyme activities have been found in various brain areas. Kato et al. (1980)
studied the distribution of POP activity in the human brain and found the highest
activity in the cerebral cortex, while other areas exhibited much lower activities. Similar
results were obtained from the rat brain by Daly et al. (1985) who also found a rather
high POP activity in the cerebellum and slightly lesser activity from the brain stem.
Cortex has been the most POP-active brain area also in the other distribution studies
conducted in rat brain (Fuse et al. 1990, Irazusta et al. 2002, Agirregoitia et al. 2005). In
the rat brain, lower POP activities were measured in the hypothalamus (Fuse et al. 1990,
Irazusta et al. 2002), hippocampus, cerebellum and amygdala (Irazusta et al. 2002).
Moreover, Agirregoitia et al. (2005) measured the same levels of enzyme activities in
the rat cortex, striatum and cerebellum. However, a valid comparison of enzyme
activities between studies is rather difficult, since most of these studies were made using
different substrates and under different conditions. Furthermore, the presence of an
endogenous POP inhibitor (Yoshimoto et al. 1982, Salers 1994, Yamakawa et al. 1994)
and other regulators of POP activity may have influenced the results (see section
2.3.2.3).
Bellemere et al. (2004) studied the distribution of the POP mRNA in rat brain and
pituitary by quantitative RT-PCR analysis and in situ hybridization. The highest
amounts of POP mRNA were found in the cerebellum and hypothalamus. Interestingly,
the mRNA amounts in the cerebral cortex were only approximately one half of the
amounts in the cerebellum (Bellemere et al. 2004), even though in terms of enzyme
activity measurements, the situation was reversed. Minor amounts of POP mRNA were
observed in the substantia nigra, medulla oblongata and spinal cord. In the high-
throughput gene expression profiling, the POP mRNA levels have been generally rather
equal among different brain areas. In human brain, the highest POP mRNA levels have
been found from the hypothalamus and prefrontal cortex, while the lowest levels were
observed from the cerebellum. In the mouse brain, substantial amounts of POP mRNA
were found from the cerebellum and preoptic area, while in the rat the highest levels
were observed from the hippocampus and dorsal striatum. In these species, the
expression of POP mRNA in the rest of the brain areas was rather equal (GNF
SymAtlas, Su et al. 2002).
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The distribution of POP between different neuronal cell types has been analyzed in
a few studies. Mentlein et al. (1990) measured the highest POP enzyme activity from rat
neurons, followed closely by astrocytes, and concluded that there was expression of
POP in both the neurons and glial cells. The enzyme activity was significantly lower in
the oligodendrocytes. Somewhat similar results were obtained by Schulz et al. (2005),
when they measured POP activities in rat neuron-, astrocyte-, oligodendrocyte- and
microglial-rich primary cultures. However, in this study, the difference between neurons
and glial cells was significant, and moderate POP activity was seen only in the
astrocytes. Furthermore, in vivo in the mouse brain, no expression of POP was seen in
the glial cells (Rossner et al. 2005).
The conclusions from these studies is that in the CNS POP is mostly present in the
neurons, but minor expression can also be present in the glial cells. However,
discrepancies between POP enzyme activity and mRNA point to some post-translational
or inhibitor-mediated regulation of POP activity in the CNS.
2.3.2.2 Subcellular localization of POP in the CNS
POP is mainly considered as a soluble cytosolic enzyme (Dresdner et al. 1982,
Schulz et al. 2005) although the membrane-bound form exists (O'Leary et al. 1995).
Membrane-bound POP has been found in the membranes of various cell lines (Chappell
et al. 1990) and in the synaptosomal fractions of bovine brain (O'Leary et al. 1995).
This form of POP is able to hydrolyze the same substrates as the soluble cytosolic form
(O'Leary et al. 1996) but its activity or amounts are somewhat lower than that of
cytosolic POP (Irazusta et al. 2002, Agirregoitia et al. 2005).
POP activity has been found in the nuclear, mitochondrial, synaptosomal and
microsomal fractions of rat and human brain while the highest activities were located in
the cytosolic fractions (Irazusta et al. 2002). However, the enzymatic activity of POP in
brain nuclear fraction may be questionable since no POP activity or protein had been
seen in the nucleus of neuronal cells in the other studies (Dresdner et al. 1982, Rossner
et al. 2005, Schulz et al. 2005). Moreover, Schulz et al. (2005) observed using
immunofluorescence techniques that POP was attached to the main component of
microtubulin cytoskeleton, tubulin, in human glioma cell lines. Furthermore, POP
appeared to be mostly localized in the perinuclear space of the cell in human glioma and
neuroblastoma cell lines, with no POP being detected in the nucleus.
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2.3.2.3 Regulation of POP enzyme activity and expression in the brain
The regulation of POP enzyme activity and gene expression has been studied to
some extent but it is still far from clear. An endogenous POP inhibitor may be
influencing the enzymatic activity of POP (see section 2.3.1.1). However, this
compound has been poorly biologically characterized.
Several substances are able to affect to the POP activity in the brain. Polyamines
(e.g. spermine, spermidine) have increased POP activity in the brain and they are able to
reverse the effect of POP endogenous inhibitor in vitro (Soeda et al. 1986). Moreover,
treatment with a non-competitive NMDA-receptor antagonist, MK-801, was able to
increase POP activity in the hippocampus and cerebral cortex of rat, while a GABAA-
receptor blocker, pentylenetetrazol, and atypical antipsychotic drug, clozapine,
decreased POP activity in the same brain areas (Ahmed et al. 2005, Arif et al. 2007).
Moreover, oxidizing agents may inhibit POP activity, at least in cell lines (Tsukahara et
al. 1990). Even changes in plasma volume and/or osmotic pressure have been reported
to affect to brain POP activity (Irazusta et al. 2001).
Furthermore, in a microarray analysis of the effects of aging on gene expression in
the mouse hypothalamus and cortex (Jiang et al. 2001), the POP gene expression in 22
months old mice was 11-fold in hypothalamus and in cerebral cortex it was 2.7 fold
higher than the values in 2 months old mice. In further support, Rossner et al. (2005)
used immunohistochemistry to demonstrate increased POP expression in the
hippocampus of aged mouse. Furthermore, POP gene expression was down-regulated
by 2.6-2.7-fold after exposures of 3 and 6 hours to an enriched environment (Rampon et
al. 2000), pointing to the age- and learning-dependent regulation of POP expression
2.3.2.4 POP and its proposed substrates in the CNS
POP has been implicated in the hydrolysis of several neuropeptides in the brain
(Table 1) of which, SP, TRH and AVP have been the best characterized in the POP
inhibitor studies and therefore, the following text is limited to these neuropeptides.
Furthermore, the involvement of POP in IP3 signalling system will be discussed in the
text below.
SP
SP and NK1Rs are distributed rather widely in the brain. The highest expression of
SP in the rat brain has been found in the cortical amygdaloid nucleus, ventral pallidum,
substantia nigra, globus pallidus and spinal cord laminae I-II followed by striatum,
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nucleus accumbens and periaqueductal gray (for reviews, see Tohyama et al. 1998,
Ribeiro-da-Silva et al. 2000). Interestingly, in the cerebral cortex, only sparse
expression of SP has been observed (Tohyama et al. 1998, Ribeiro-da-Silva et al. 2000)
although the highest POP activities have been detected in the cortex (see section
2.3.2.1). NK1Rs are also widely distributed in the CNS, but similarly to SP, their
expression is only moderate in the cerebral cortex (Yip et al. 2000, Yip et al. 2001).
SP has been a target of pharmaceutical interest, since it has been associated with
various physiological functions and diseases in the CNS. In general, SP is recognized as
a neurotransmitter involved in pain signalling from peripheral tissues to CNS, since
there are high concentrations of SP and NK1R in the dorsal root of spinal cord (for
review, see Harrison et al. 2001). However, involvement of SP in memory and learning
served originally as a rationale to develop POP inhibitors to prevent the hydrolysis of
this peptide (Kato et al. 1980a). Injections of SP to the brain areas have shown positive
reinforcement effect on learning and systemic injection has been effective in alleviating
age-related learning deficits (Huston et al. 1995, Hasenohrl et al. 2000). The mechanism
of action for SP in memory and learning is unclear, but it presumably operates as a
reinforcer of cortical cholinergic neurons, affecting their activity and acetylcholine
(ACh) release (Hasenohrl et al. 2000), and possibly acting as an enforcer of long-term
potentiation (LTP) in hippocampus (Langosch et al. 2005). In some studies, POP
inhibitors have shown memory enhancing effects (Toide et al. 1995a, Toide et al. 1997)
but the effects of these inhibitors on the SP levels in the brain are debatable (Table 2).
SP is also claimed to be associated with fear-related behaviour since it is released by
adverse stimulation, and anxiolytic and antidepressant drugs are able to reduce SP levels
in the brain (Raffa 1998, Hasenohrl et al. 2000). Moreover, in animal models, SP
agonists have showed anxiogenic effects while SP antagonists have reduced anxiety
(Hasenohrl et al. 2000, Hökfelt et al. 2003). Nevertheless, the association of POP with
SP in pain transmission or in anxiety has not been adequately studied although some
changes in serum POP activity have been observed in patients suffering from
fibromyalgia and psychiatric disorders (Table 3).
SP has been linked to the neurodegenerative diseases such as Alzheimer's and
Parkinson's disease. In both diseases, depletion of SP in the brain has been observed but
not invariably (Beal et al. 1987, Raffa 1998). The association of SP to Parkinson's
disease appears to be more convincing, since GABAergic efferent nigrostriatal neurons
are known to use SP as a neurotransmitter (Emson et al. 1979, McGinty 2007).
Moreover, parallel alterations of brain POP enzyme activity have been reported in both
diseases (Mantle et al. 1996). POP has also been associated with the generation of ?-
amyloid protein in Alzheimer's disease (Kato et al. 1997, Shinoda et al. 1997).
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However, the changes in POP enzyme activity in brain are not unambiguous and POP
activity changes in the generation of ?-amyloid are likely to result from neuronal
degeneration (Petit et al. 2000, Laitinen et al. 2001, Rossner et al. 2005).
Several studies have connected SP to the early development of the brain due to the
changes in its expression during the embryonic period, perhaps reflecting a role for SP
as a neuroprotective agent or even as a growth factor in the brainstem (for review, see
Raffa 1998). Interestingly, also POP enzyme activity levels have been shown to
increase during embryonic development and to decrease during the postnatal period
(Agirregoitia et al. 2003b, Agirregoitia et al. 2007) and some studies have postulated
that POP may function as a neuroprotective agent (Rossner et al. 2005). Nevertheless, it
is not known whether POP is involved in these events through its hydrolytic or non-
catabolic functions.
TRH
TRH and TRH-receptors are distributed throughout the human and rat brain while
the highest amounts are located in the hypothalamus (Lechan et al. 1982, Parker et al.
1983, Mantyh et al. 1985), especially in the paraventricular nucleus (Jackson et al.
1985). Rather high amounts of TRH/TRH-receptors have also been detected in the
olfactory bulb, amygdala, dentate gyrus of hippocampus and entorhinal cortex (Parker
et al. 1983, Mantyh et al. 1985). The distribution pattern of the mRNA's of TRH-R1 and
TRH-R2 are somewhat different. TRH-R2 is present preferentially in the cortex and
thalamus of rat brain, while R1 is mostly present in the hypothalamus (Sun et al. 2003).
Interestingly, similarly to the situation with the TRH/TRH-receptors, high amounts of
POP mRNA (Bellemere et al. 2004) and moderate POP enzyme activities have been
measured in the hypothalamus (Fuse et al. 1990, Irazusta et al. 2002).
The most important CNS function of TRH is the control TSH release via the
stimulatory input from the hypothalamus in the hypothalamic-pituitary-thyroid (HPT)
axis (for reviews, see Fliers et al. 1998, Nillni et al. 1999, Lechan et al. 2004). However,
in the context of the POP research, the ergotropic effects (arousal, sleep, cognition,
locomotor activation and antidepressant) of TRH, especially in cognition, have been a
focus of interest. The cognitive aspects of TRH are likely to be mediated by enhanced
cortical ACh turnover in the frontal cortex and hippocampus (Toide et al. 1993, Itoh et
al. 1994, Ogasawara et al. 1996). As mentioned before, POP is able to deaminate TRH
or His-Pro-NH2 product after PAP I/PAP II/thyroliberinase cleavage in vitro
(Yanagisawa et al. 1980) but POP inhibitors have failed to modify TRH levels in cell
line experiments (Mendez et al. 1990, Salers et al. 1991). However, in animal studies,
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treatment with a POP inhibitor JTP-4819 has restored decreased TRH-like
immunoreactivity (TRH-LI) in the cortex but not in the hippocampus of young rats
(Shinoda et al. 1995, Toide et al. 1996) and another POP inhibitor, S17092, was able to
increase TRH-LI in the rat cortex in a dose dependent manner (Bellemere et al. 2005).
However, the lack of effect in cell line experiments and the controversial results in vivo
cast serious doubt on the ability of POP inhibitors to influence the TRH/TRH-LI levels
in the brain. Interestingly, despite the above findings, no effects of POP inhibitors to the
regulation of physiologically important HPT-axis have been reported.
AVP
AVP synthesis takes place together with another proposed POP substrate, oxytocin
(Walter et al. 1971), within the neurons of SON and PVN. AVP is synthesized with its
carrier protein or neurophysins (NPI and NPII) as a part of a precursor or pre-
prohormone in the perikarya of the mangocellular neurons. This precursor is packaged
into granules and transported to the axon terminals in the neurohypophysis and the
cleavage and maturation of the peptide occurs during this transport. Although most of
the AVP neurons are located in the SON and PVN, projecting to the hypophysis, a small
population of these AVP synthesizing parvocellular neurons are located in the PVN, bed
of nucleus of the stria terminalis, medial amygdala and suprachiasmatic nucleus and
their projections remain within the brain (for reviews, see Bisset et al. 1988, Rinaman
2007, Caldwell et al. 2008). The main regulator of AVP release under normal
conditions is plasma osmolality or blood volume/pressure mediated via baro-, stretch-
and chemoreceptors (Bisset et al. 1988, LeJemtel et al. 2007). Changes in plasma
osmolality can also affect the gene expression of AVP (Hayashi et al. 2006).
Furthermore, cholinergic and GABAergic neurons may act as inhibitory or excitatory
transmitters for AVP release (Bisset et al. 1988). Sex hormones are also able to regulate
the release of AVP (Fink et al. 1996).
In the peripheral tissues, V1aR is mostly present in the liver, smooth muscle
(Birnbaumer 2000) and its mRNA is abundantly present in the hypothalamus and
moderately in the hilus of hippocampus, granule cells of cerebellum, lateral septum,
ventral tegmental area and brain stem (Ostrowski et al. 1994). However, its
physiological function remains rather unclear except that it may be involved in the
behavioral effects of AVP (see below). V1bR stimulates the release of
adrenocorticotropin from the anterior pituitary but these receptors are widely distributed
throughout the CNS. High amounts of immunoreactive V1bR are present in the
hypothalamus, olfactory tubercule, hippocampal CA fields, while it is moderately
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present in the frontal cortex, caudate putamen, substantia nigra, dentate gyrus of
hippocampus and granule cell layer of cerebellum (Hernando et al. 2001).
Autoradiographie studies have confirmed the V1R distribution in the CNS (Brinton et
al. 1984). V2R is present mostly in the peripheral tissues, in the distal nephron,
regulating water reabsorption (see section 2.3.1.2). These three AVP receptors are G-
protein coupled receptors. V1Rs can induce IP3-mediated Ca
2+-release from
endoplasmic reticulum while V2R activation triggers the activation of cAMP mediated
opening of the water channel thus increasing water reabsorption (Birnbaumer 2000,
Caldwell et al. 2008). The distribution of CNS receptors of AVP is rather similar with
the mRNA (Bellemere et al. 2004) and enzyme activity distribution of POP (Fuse et al.
1990, Irazusta et al. 2002).
Similar to the situation with TRH, the interest of POP and AVP has focused on the
role of AVP as a behavioral regulator. AVP has been implicated as being involved in
social behaviors such as aggression and affiliation, social and non-social memory and to
anxiety and depression. The behavioral effects of AVP are evidently mediated through
V1aR and V1bR, since the aggression, social and spatial memory are impaired in V1aR
and V1bR knock-out mice. Furthermore, injection of AVP to lateral septum can increase
social recognition and male aggression in mice (for review, see Rose et al. 2002,
Caldwell et al. 2008). The exact mechanism of the AVP regulated behavioral effects are
not known, but interactions with serotonin (5-HT) (Ferris et al. 1999) and LTP in the
hippocampus have been reported (Sarvey et al. 1989, Dubrovsky et al. 2003). POP
inhibitors have shown possibly AVP-mediated memory and cognitive improvements in
some animal models (Toide et al. 1995a, Toide et al. 1997) and acute administration of
S17092 and JTP-4819 has increased AVP-like immunoreactivity (AVP-LI), especially
in the hippocampus of young rats (Table 2, Toide et al. 1996, Bellemere et al. 2005).
However, no changes of the AVP levels in the hippocampus or cortex were seen after
repeated administration of POP inhibitors (Table 2, Toide et al. 1995a, Toide et al.
1995b, Shinoda et al. 1996, Bellemere et al. 2005) pointing to some discrepancies in the
effects of POP inhibitors. Similarly to TRH, no studies have reported the involvement
of POP inhibitors in the antidiuretic properties of AVP nor has the effect of POP
inhibitors been examined on the AVP levels in the hypothalamus.
IP3
IP3 is a second messenger that especially affects the release of Ca
2+ from the rough
endoplasmic reticulum (RER) (Ferris et al. 1992, Berridge 1993, Hokin et al. 1993). IP3
mediated Ca2+ release has been linked to several important cell functions such as
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activation of transcription factors, e.g. CREB (Furuichi et al. 1995) and NO (Iino 2006).
Furthermore, IP3 signalling is involved in LTP and long-term depression (LTD), two
well established parameters in learning and memory (Lynch et al. 1991, Khodakhah et
al. 1997, Jun et al. 1998, Fujii et al. 2004). IP3 regulated LTP and LTD has been
observed in hippocampal CA1 pyramidal cells (Jun et al. 1998, Fujii et al. 2004), one of
the most important areas of memory and learning, and in cerebellar Purkinje cells
(Khodakhah et al. 1997). In hippocampus, LTP is induced by the activation of N-
methyl-D-aspartate (NMDA) glutamate receptors (Bliss et al. 1993, Fujii et al. 2004).
Recently, several studies have connected POP and IP3 signalling. Firstly, Williams
et al. (1999) observed that a lithium resistant mutant Dictyostelium discoideum was lack
of POP encoding gene. Thereafter, they observed that mutant Dictyostelium had 3-fold
IP3 levels after 10 mM of LiCl administration when compared to the wild type cells
(Williams et al. 1999). As a further support, Schulz et al. (2002) generated POP
antisense glial cell line and observed an inverse correlation between IP3 and POP
expression. Similar relationships between POP enzyme activity and IP3 levels were
obtained when POP inhibitors were applied to the wild-type Dictyostelium (Williams et
al. 1999) and human glioma and neural cell lines (Schulz et al. 2002). These findings
have proposed that POP may be involved in regulation of IP3 signalling pathway.
Interestingly, administration of POP inhibitor did not affect to the functions cAMP
pathway, but cAMP was increased in the POP antisense glial cell line (Schulz et al.
2002).
The mechanism of how POP control over IP3 synthesis is not clear. POP is not a
direct target for Li+ since it had no effect to the POP activity (Williams et al. 1999,
Cheng et al. 2005). Furthermore, POP does not degrade IP3 metabolizing enzymes,
since Williams et al. (1999) showed increased IP3 degradation in the mutant
Dictyostelium. Therefore, POP may be able to inhibit MInsPP that generates IP3 from
IP6 (Harwood et al. 2003). POP inhibition activates MInsPP and therefore increases the
synthesis of IP3. Another connection for POP to the IP3 and Ca
2+ signalling is the PEP-
19 that is able to influence Ca2+ signalling via binding to calmodulin. Brandt et al.
(2005) revealed that during incubation of porcine brain homogenates with POP, a
peptide sequence that is minimum domain of PEP-19 to bind calmodulin, disappeared.
Moreover, Williams et al. (2000) studied the effects of Li+, VPA and carbamazepine in
the POP mutant Dictyostelium cell line. They observed that lack of POP gene made
mutant Dictyostelium resistant also to VPA induced IP3 depletion. Furthermore, the
administration of two different POP inhibitors, Z-Pro-Prolinal and BOC-Glu (NHO-
Bz)-Pyr, to the rat neural explant cultures block the expansive effects of Li+, VPA and
carbamazepine to the growth cone area. Similar effect was obtained using pure inositol
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(Williams et al. 2000). Recently, Cheng et al. (2005) revealed that in vitro VPA
inhibited recombinant human POP activity at therapeutic blood levels of the drug (1
mM) and they even suggested that POP may be a direct target for VPA. These findings
are suggesting that IP3 signalling pathway is involved in mood control and may be a
common target of a very diverse group of mood stabilizing drugs, such as Li+, VPA and
carbamazepine (Hokin et al. 1993, Williams et al. 2000, Agam et al. 2002, Cheng et al.
2005, Williams 2005) and that POP may be involved in the regulation of these actions.
Interestingly, all previously discussed neuropeptides (SP, TRH and AVP) influence
the IP3 second messenger system via their G-protein receptors. However, the possible
association between POP, neuropeptides and IP3 signalling has not been clarified. One
serious complication against the hypothesis that POP significantly influences the
metabolism of neuropeptides in the brain is their different cellular localization.
Neuropeptides are released outside the cell directly from the storage vesicles whereas
POP is mainly an intracellular enzyme. How is it possible for an intracellular enzyme to
metabolize neuropeptides released outside the cell? Membrane-bound POP may be able
to cleave neuropeptides in the vicinity of the cell membrane assuming that it is
orientated extracellularly. However, relatively low activity and/or amounts of
membrane-bound POP exist in the brain (Irazusta et al. 2002, Agirregoitia et al. 2003b)
and this is probably insufficient to significantly contribute to the metabolism of
neuropeptides. Furthermore, even though intracellular receptors for SP (Baude et al.
1998, Levesque et al. 2007) and TRH (Sun et al. 2003, Cook et al. 2004) have been
found, these are more likely internalized receptors being recycled in a desensitization
pathway (Hökfelt et al. 2003, Sun et al. 2003, Cook et al. 2004) and their agonists are
not able to activate the receptors when they are in the intracellular space. This
contradiction may be the reason for inconsistent effects of POP inhibitors on
neuropeptide levels in the brain. Therefore, the participation of POP on IP3 signalling in
the brain could explain some of the neuropeptide-like results obtained with POP
inhibitors in animal studies, such as the beneficial effects of POP inhibitors to memory
and learning. Nevertheless, no significant changes in rat brain cortical or hippocampal
IP3 levels were seen in vivo after five consecutive doses (9 µmol/kg) of JTP-4819
administered every 12 h (Jalkanen et al. 2007). However, the distribution of POP is
apparently restricted to only a moderate amount of neurons in the cerebral cortex and
therefore the effects of POP inhibitors to the IP3 levels may be overlooked in these
measurements.
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2.3.3 POP in the serum
Various studies have reported some changes of POP activity in human serum in
several diseases (Table 3). These analyses have been made with a fluorometric method,
using Z-glycyl-prolyl-4-methylcoumarinyl-7-amide as a substrate, by the method of
Goossens et al. (Goossens et al. 1992, Goossens et al. 1996).
Table 3. Effects of various diseases to POP enzyme activity in human serum
Disease Effect to POP
activity
Reference
Alcoholism ? Maes et al. 1999a
Anorexia nervosa ? Maes et al. 2001
Depression ? Maes et al. 1994, Maes et al. 1995
Fibromyalgia ? Maes et al. 1998b
HIV infection ? Goossens et al. 1996
Malaria infection ? Goossens et al. 1996
Mania ? Maes et al. 1995
Prostate carcinoma ? (hormonally
treated)
? (untreated)
Goossens et al. 1996
Post-traumatic stress disorder ? Maes et al. 1999b
Renal hypertension ? Goossens et al. 1996
Schizophrenia ? Maes et al. 1995
Stress induced anxiety ? Maes et al. 1998a
?, increased POP serum activity; ?, decreased POP serum activity
However, the true nature of POP activity in the serum is questionable. The
examined POP was partially purified from bovine serum, and interestingly, this serum
POP failed to hydrolyze several fluorometric substrates and had significantly lower
specificity towards several well-established POP substrates - such as bradykinin and SP
- than tissue POP, suggesting that perhaps it represents a previously unknown protease
with POP-like functions (Cunningham et al. 1998). Cunningham and O'Connor (1997)
also found that another POP-like enzyme, named as Z-Pro-Prolinal-insensitive POP
(ZIP) in bovine serum. This enzyme was resistant to the classical POP inhibitor Z-Pro-
Prolinal, but still capable of hydrolyzing Z-glycyl-prolyl-4-methylcoumarinyl-7-amide
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substrate (Cunningham et al. 1997b). After this finding, ZIP was purified from bovine
serum and it was identified as an 87 kDa monomer enzyme exhibiting several
similarities to POP (Birney et al. 2001). ZIP was found to have the ability to hydrolyze
some proline-containing neuropeptides (angiotensin and TRH) but failed to degrade
others (SP, bradykinin and neurotensin) (Birney et al. 2001). In a further study, the ZIP
protein sequence was analyzed and it was identified as seprase/fibroblast activation
protein ? (FAP, EC 3.4.21.B28). FAP is resistant to another well documented POP
inhibitor, JTP-4819, but still capable of hydrolyzing the Z-glycyl-prolyl-4-
methylcoumarinyl-7-amide substrate (Collins et al. 2004). Nevertheless, ZIP or
FAP/Seprase (Aoyama et al. 1990) can be inhibited with cysteine protease inhibitors
(Birney et al. 2001). Breen et al. (2004) studied the POP and ZIP enzyme activities in
the serum of bipolar disorder and schizophrenic patients using Suc-Gly-Pro-MCA as the
substrate. However, no significant differences were found in POP activity between two
groups (Breen et al. 2004). Therefore, the alterations of serum POP-like activity in
diseases may reflect the enzymatic activities of ZIP/FAP rather than POP, especially
when measured with Z-glycyl-prolyl-4-methylcoumarinyl-7-amide.
FAP was first identified as a 170 kDa homodimer, containing two 97 kDa subunits,
in the malignant melanoma cell line LOX (Aoyama et al. 1990). Similar to the DPPIV,
the closest relative to POP (Venäläinen et al. 2004), FAP is a type II membrane protein,
capable of degrading Pro-Xaa –bond, and its sequence is rather similar to that of DPPIV
(Havre et al. 2008). However, FAP has generally not been found in normal adult tissue
but it is believed to be involved in wound healing and various cancers (Garin-Chesa et
al. 1990, Havre et al. 2008). This may connect FAP to the increased POP-like activity in
cancer (Goossens et al. 1996), but the membrane-bound nature of FAP is a true
dilemma considering its POP-like activity in serum.
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3 AIMS OF THE STUDY
The objective of this study was to localize POP protein in various tissues, also at the
cellular and subcellular levels, and to determine associations of POP with specific
neuronal neurotransmitters and substrates in the brain. The specific aims of this
neuroanatomical study were:
1. To examine the distribution and amounts of POP protein in the mouse whole-body
and peripheral tissues, and compare them to the enzymatic activity (I).
2. To determine and quantitate the amounts of POP protein in the main functional areas
of human and rat brain and compare it to the previous results of POP distribution as
assessed by enzyme activity measurements and mRNA in situ hybridization (II).
3. To clarify the expression of POP at the cellular and subcellular levels in rat brain and
to study its associations with specific neuronal neurotransmitters (III).
4. To study the spatial associations of POP and its suggested substrates, SP and IP3
receptor type 1, in the brain (IV).
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4 MATERIALS AND METHODS
4.1 Chemicals
All chemicals used were purchased from Sigma-Aldrich (St. Louis, MO, USA)
unless an alternative source is specified in the text. NaCl was from FF-Chemicals AB
(Yli-Ii, Finland) and ethanol from Altia (Helsinki, Finland).
4.2 Study subjects and human brain sampling (II)
The study group consisted of 5 Caucasian individuals (4 males, 1 female; age-range
36–77 years; mean age 53.5 ± 10.6 years; postmortem delay 14.8 ± 9.2 h; mean ± SD)
free of psychiatric illnessis. The subjects died suddenly because of myocardial
infarction (4) and rupture of the aorta (1).
Human brains used were obtained during clinical necropsy at the Department of
Forensic Medicine, University of Oulu, Finland, and the Department of Forensic
Medicine, University of Kuopio, Finland. The Ethics Committee of the University of
Oulu and the University of Kuopio and the National Institute of Medicolegal Affairs,
Helsinki, Finland, approved the study.
Frozen left hemisphere was cryosectioned using a heavy-duty cryomicrotome (LKB
2250, LKB, Stockholm, Sweden) into 100 ?m horizontal (canto-meatal) sections, which
were transferred to the gelatinized glass plates (100 × 220 × 1 mm) as previously
described (Hall et al. 1996). The sections were allowed to air dry before they were
stored with dehydrating agents at ? 25 °C until use.
4.3 Animals and tissue preparation (I-IV)
Wistar rats (II-IV) were supplied from National Laboratory Animal Center,
University of Kuopio (II-IV). NMRI mice (I) were supplied from National Laboratory
Animal Center, University of Helsinki. Animals were housed under controlled
conditions and had free access to food and water.
For whole-body immunohistochemistry (I), mice were deeply anesthetized using
chloral hydrate, perfused, and quickly placed into isopentane cooled with dry ice for 30
sec and then stored at -70 °C until sectioning. Frozen animal was cryosectioned to
sagittal sections using a heavy-duty cryomicrotome (LKB 2250, LKB, Stockholm,
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Sweden). For paraffin embedded tissue samples (I), animals were deeply anesthetized
using chloral hydrate and then perfused with 4% paraformaldehyde solution. After
perfusion, the internal organs were removed and placed to the 10% paraformaldehyde
solution until paraffin embedding and sectioning.
For frozen sections immunohistochemistry, rats were killed by decapitation and
brains were immediately removed, frozen and then stored at -70 °C until sectioning to
the coronal brain sections by cryostat (II). For floating sections (III-IV), rats were
deeply anesthetized using chloral hydrate and then perfused using saline followed by
4% paraformaldehyde in 0.1 M phosphate buffer (PB), decapitated, and the brains were
removed and placed into cryo-protectant solution and stored at -20 ºC until sectioning.
For electron microscopy (III), rats were perfused using saline followed by fixative
containing 4% paraformaldehyde and 0.05% glutaraldehyde in 0.1 M PB, pH 7.4. The
brains were removed and washed with PB before placing into the cryo-protectant
solution and stored at -20 ºC. After vibratome sectioning, selected brain areas were cut
to 1 mm2 pieces and placed in 10% and 20% glycerol in PBS for 1 hour and 30%
glycerol in PB overnight before freeze-substitution.
For enzyme activity measurements (I), tissues were removed, quickly frozen in
liquid nitrogen and thereafter stored at -70 °C until homogenized in 5 vol. of assay
buffer (0.1 M Na-K-phosphate buffer, pH 7.0). The homogenate was centrifuged at
16,000 g, 4 °C, for 20 min. Aliquots of supernatant were frozen and stored at -70 °C.
All animal procedures were conducted according to the Council of Europe
(directive 86/609) and Finnish guidelines, and approved by the local animal ethics
committee and State Provincial Office of Eastern Finland.
4.4 6-OHDA (6-hydroxydopamine) lesion (III)
Stereotaxic surgery was performed under isoflurane inhalation anaesthesia. The rat
was placed in a stereotaxic apparatus (Stoelting, Wood Dale, Illinois, USA) and 4 ?l of
the 6-OHDA-infusion (2.0 ?g/?l) were injected for 8 min to the final infusion site near
substantia nigra using motor-driven slow-motion syringe pump (CMA/102, CMA
Microdialysis, Solna, Sweden).  Six weeks after the lesion, the animal was perfused,
decapitated and brains were removed and stored as described above.
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4.5 Preparation and specificity of polyclonal POP antibody (I-IV)
The preparation of polyclonal POP antibody has been described in Venäläinen et al.
(2006). Briefly, purified E. coli expressed recombinant human POP (Venäläinen et al.
2002)  was used to generate antibodies against POP in a hen. Two 50 ?g protein
dosages (in 50% Freund's complete adjuvant), with two weeks interval, were injected to
hens. Egg yolks were collected and IgY´s were isolated by the water dilution method
(Kokko et al. 1994) and POP-specific IgY was then purified by affinity chromatography
using a HiTrap NHS column coupled with purified POP (Venäläinen et al. 2006).
Second patch of polyclonal POP antibody was generated using the same methods. In the
specificity tests it proved to have same characteristics as the first patch.
Antibody specificity in rat brain was assayed by western blotting using rat brain
homogenates from the whole brain, cerebral cortex and hypothalamus while purified
recombinant pig POP served as a control (II-IV). In all experiments, only one band at
around 80 kDa, corresponding to the full length POP, was detected (Fig. 4A).  We also
studied whether the antibody was able to react with human dipeptidyl peptidase IV
(DPPIV, EC 3.4.14.5, a gift from GlaxoSmithKline), the closest relative of POP
(Venäläinen et al. 2004). Amounts as high as 2.5 ?g of pure DPPIV did not react with
the anti-POP IgY in western blot experiments (data not shown). Moreover,
preadsorption control was used. POP-antibody solution (dilution 1:1000) was
preadsorbed with purified recombinant pig POP (24 µg) for 60 min at room temperature
and thereafter the staining was carried out normally. Control section remained free of
POP-immunoreactivity (III).
Antibody specificity in mouse tissues was assayed by western blotting (I) using
mouse tissue homogenates from the whole brain, liver, kidney and testis while purified
recombinant pig POP served as a control. In all experiments, only one band at around
80 kDa, corresponding to the full length POP, was detected (Fig. 4C).
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Figure 4A-C. The specificity of POP antibody confirmed by western blot from rat brain
homogenates (A) and mouse tissue homogenates (C), and by preadsorption control from
rat brain section (B). In all experiments, only one band at around 80 kDa was seen.
CTX, rat cerebral cortex; HT, rat hypothalamus; WB, rat whole brain.
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4.6 Immunohistochemical and microscopic methods
4.6.1 Light microscopic immunohistochemistry (I-III)
For frozen and whole-body sections (I, II), a basic immunohistochemical staining
procedure was used. Endogenous peroxidase was blocked with 0.1 % NaN3 and 0.3 %
H2O2 in phosphate buffered saline (PBS) and sections were incubated in blocking
solution (3 % BSA in PBS) for 30 min to reduce non-specific staining. Primary
antibody against POP was added and the sections were incubated for 48 hr at +4 °C,
followed by 2 hour incubation in room temperature with HRP conjugated secondary
antibody. Details of the antibody dilutions are shown in Table 4. Immunocomplexes
were detected by using DAB with a nickel enhancer in whole-body and human brain
sections, and with a cobalt enhancer in rat brain sections.
Immunohistochemistry for the free-floating sections (III) was performed with a
protocol modified for frozen sections. Sections were incubated in blocking solution (10
% normal goat serum (Chemicon International Inc., Temencula, CA, USA) in PBS
containing 0.5% Triton X-100) for 40 min to minimize non-specific staining.
Thereafter, the primary antibody against POP was added and the sections were
incubated for 48 hr at +4 °C. After the primary antibody incubation and the subsequent
PBS washes, there was an overnight incubation at +4 ºC with HRP conjugated
secondary antibody (Table 4). Immunocomplexes were detected by using DAB with a
nickel enhancer.
For paraffin-embedded mouse tissues (I), immunohistochemistry was performed
using modified frozen-sections protocol. Sections were dewaxed in xylene, rehydrated
with graded alcohols and washed with 0.1 M PBS. The antigen retrieval was processed
in a microwave oven in citrate buffer (pH 6.0) and thereafter the staining was carried
out normally. Finally, the slides were counterstained with Mayer’s haematoxylin,
washed, dehydrated and mounted with Depex (BDH, Poole, UK).
Light-microscopy immunohistochemistry photomicrographs (I, III) were captured
by a digital camera connected to the Olympus BX40 microscope and DP50 Digital
Camera (Olympus Corporation, Tokyo, Japan) and corrections to brightness and
contrast, were made with Adobe Photoshop CS2 software (version 9.0, Adobe Systems
Incorporated, Mountain View, CA, USA). The identification and nomenclature of the
brain structures (II, III) was based on the rat brain atlas by Paxinos et al. (1997), human
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brain atlas by Mai et al. (2004) and cresyl violet staining of the corresponding specimen
level of human brain sections. The identification and nomenclature of mouse internal
organs (I) were based on the atlas by Iwaki et al. (2001).
Whole-body section photomicrographs (I) were captured using ImageQuant ECL
RT imaging device (GE Healthcare, Buckinghamshire, UK) and
immunohistochemically processed frozen-sections (II) were scanned by a Bio-Rad
(Hercules, CA, USA) scanner (GS-710 Calibrated Imaging Densitometer).
Immunohistochemically processed mouse whole-body section photomicrographs
(I) and rat and human brain sections (II) were diverted from grayscale images to color
coded images with Scion Image software (version alpha 4.0.3.2, Scion Corporation.
Frederick, MD, USA). Only minor corrections to brightness and contrast and pixel
errors were made with Adobe Photoshop CS2 (version 9.0, Adobe Systems
Incorporated).
4.6.2 Immunofluorescent microscopy (I, III, IV)
In colocalization studies, the double and triple-labelling immunofluorescence
technique was used by modifying free-floating sections protocol (see above). All the
primary antibodies and their dilutions used are presented in Table 4. Double- (I, III, IV)
or triple-labelling immunofluorescence (I, IV) with POP-antibody followed after the
first or second secondary antibody incubation. The procedure in the second and/or third
staining was similar to the first and 40 min incubation with 10 % NS blocking solution
was used to minimize cross-reactions between antibodies. Furthermore, in order to
minimize the cross-reactions, the primary antibodies used in double and triple-label
immunofluorescence were chosen from different species as shown in Table 4.
Vectashield with DAPI (Vector Laboratories, Burlingame, CA, USA) was used as a
mounting medium to demonstrate the nuclei of the cells.
In double- and triple-labelled immunofluorescence, control stainings were carried
out by omission of primary antibodies. No evidence of any staining was observed in
these negative controls.
Immunofluorescence photomicrographs were captured by a digital camera
connected to the Olympus BX40 microscope and DP50 Digital Camera (Olympus
Corporation, Tokyo, Japan) and corrections to brightness and contrast, and converting
of red images to magenta (III) were made with Adobe Photoshop CS2 software (version
9.0, Adobe Systems Incorporated).
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4.6.3 Laser scanning microscopy (I, III, IV)
Fluorescent double-labelled (I, III, IV) sections were analyzed and photographed
using Ultra VIEW Confocal Imaging System (PerkinElmer, Cambridge, UK) equipped
with an argon-krypton laser mounted on an inverted Nikon Eclipse TE300 microscope
(Nikon Corporation, Tokyo, Japan). Triple-labelled (IV) sections were photographed
using an upright microscope (Leica DM5000B, Leica Microsystems Inc.) with
broadband laser confocal device (Leica TCS SP5, Leica Microsystems Inc.).
After capturing images with an imaging device, confocal double- and triple-labelled
immunofluorescence micrographs were converted to RGB images and colorized with
the corresponding colors (blue, green and red (I, IV), and red to magenta (III)) using
Adobe Photoshop CS2 software (version 9.0, Adobe Systems Incorporated). Only minor
corrections to brightness and contrast in the pictures were made.
4.6.4 Post-embedding immunoelectron microscopy (III)
Tissue samples were processed with the freeze-substitution technique (Reichert
AFS, Leica/Reichert, Vienna, Austria) and low-temperature embedding using Lowicryl
HM20 (Electron Microscopy Sciences, Hatfield, PA, USA). Ultra thin cryosections
were sectioned using an ultramicrotome (Ultracut E; Reichert-Jung, Austria) and POP-
immunohistochemistry was performed using the following protocol: Sections were first
incubated in 50 mM NH4Cl blocking solution for 10 min and in 5% BSA (bovine serum
albumin, containing 0.1% fish skin gelatin) solution for 20 min followed by washes in
0.1% acetylated BSA (BSA-c) and 0.1% Tween 20 in PBS. Primary antibody
incubation for 1 hr with POP-antibody was performed and followed by washes using
0.1% BSA-c and 0.1% Tween 20 in PBS. POP-immunocomplexes were detected using
rabbit anti-chicken IgY with 15 nm gold label (Product #825.222, Aurion, Wageningen,
The Netherlands) as a secondary antibody. After 30 min secondary antibody incubation,
6x5 min PBS washes followed. Thereafter the sections were post-fixed using 5%
glutaraldehyde in PBS for 5 min before further fixation with 5% uranyl acetate and lead
citrate. Omission of primary antibodies served as negative staining and remained free of
gold particles (see Fig. 10A in III).
Sections were viewed with JEM-1200EX (JEOL Ltd., Tokyo, Japan) transmission-
electron microscope (TEM).
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4.7 Tissue fractioning and western blot analysis (I)
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Product #78833, Pierce
Biotechnology) was used to extract nuclear and cytoplasmic fractions from the brain,
liver, kidney and testis. The tissues were homogenized in cytoplasmic reagent with
EDTA-free Halt protease inhibitor cocktail (Product #78410, Pierce Biotechnology).
After homogenization, secondary cytoplasmic reagent was added and the fraction was
centrifuged for 5 min at 16,000g, supernatant (cytoplasmic fraction) was removed and
stored at -80 ºC. Remaining pellet was washed twice using PBS and thereafter
resuspended to the nuclear reagent, incubated for 40 min in ice and then centrifuged for
10 min at 16,000g. Supernatant (nuclear fraction) was removed and stored at -80 ºC
until use.
The purities of nuclear and cytoplasmic fractions were confirmed by western blot
(Fig. 9B in IV) using anti-histone H3 goat anti-rabbit polyclonal antibody (nuclear
marker, dilution 1:5000, Product #H0164, Sigma-Aldrich) and anti-tubulin monoclonal
antibody (cytoplasmic marker, dilution 1:5000, Product #05-829, clone DM1A, Upstate,
Temecula, CA, USA). In all western blot analyses, standard SDS-PAGE, transfer and
blocking techniques were used and chemiluminescence images were captured using
ImageQuant ECL RT imaging device (GE Healthcare).
The distribution of POP between nuclear and cytoplasmic fractions of the brain and
peripheral tissues was assayed by western blot analysis using anti-POP (described
above) as the first antibody, and goat anti-chicken IgY-HRP conjugate (dilution
1:10000) as a second reporter.
4.8 Enzyme activity assay (I)
The POP activity assay was performed as described earlier (Venäläinen et al. 2002).
Briefly, tissues were frozen in liquid nitrogen after removal and stored at ?70° until
homogenized in 5 vol. of assay buffer (0.1 M Na–K-phosphate buffer, pH 7.0). The
homogenate was centrifuged at 10,000 g, 4 °C, for 20 min. Aliquots of supernatant were
frozen and stored at ?70 °C. An enzyme solution (10 ?L of tissue homogenates) was
preincubated in a 48-microtiterplate with 465 ?l of assay buffer for 30 min at 30°. The
reaction was initiated by adding 25 ?l of substrate (4 mM Suc-Gly-Pro-AMC) and the
plates were incubated for 60 min at 30 °C. The reaction was terminated by the addition
of 500 ?l of 1 M sodium acetate buffer (pH 4.2). The formation of AMC (7-amino-4-
methylcoumarin) was measured fluorometrically using a Wallac 1420 VICTOR2
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fluorescence plate reader (PerkinElmer, Waltham, MA, USA). The excitation and
emission wavelengths were 360 and 460 nm, respectively. AMC dilutions served as a
control in the measurements. The variation of results between 10 different
measurements was ± 6.80 % (± SEM).
4.9 Semiquantitative analysis (I-IV)
Immunohistochemically processed sections (I, II) were analyzed using Bio-Rad
QuantityOne 4.5.1 software. In optical density (OD) analysis brain regions were
delineated with the freehand-tool of the software. The OD values of different brain areas
were compared to the mean values of corpus callosum (I) or brain (II). The background
values of each brain area (background obtained by control staining without primary
antibody) were subtracted from raw data values of the same brain area. The averages
and SEM of optical densities from each area were calculated using an Excel
spreadsheet.
The percentages of colocalizations in double-labeling immunofluorescence were
calculated comparing colocalized neurons with POP containing neurons and using
Abercrombie's correction (Abercrombie et al. 1946) (III, IV). The colocalization
percentage for each area was calculated from at least 3 different animals and from 2-4
different immunostainings. The average of counted cells per region was approx. 20 (III,
IV) and the number of counted slides per brain area varied from 3 to 7.
4.10 Statistical analyses (I-IV)
Statistical analyses were performed using GraphPad Prism (version 4.03, GraphPad
Software, Inc., San Diego, CA, USA). One-way ANOVA followed by Newman-Keuls
multiple comparison test was performed to analyze differences between the groups. To
detect a significant difference between groups (II, III), two-tailed student t-test was
performed. Statistically significant differences were considered at P < 0.05.
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5 RESULTS
5.1 Body distribution of POP protein and POP activity in the mouse (I)
5.1.1 Whole-body immunohistochemistry
In mouse whole-body sections, POP protein was widely but unevenly distributed
(Fig. 5A). The highest amount of POP protein was observed in the brains (Fig. 5A, Fig.
5B), but almost equally high levels of POP immunoreactivity was found in the kidney,
testis and thymus (Fig. 5A, Fig. 5B). POP was also clearly present in the urinary
bladder, lungs (Fig. 5A, Fig. 5B) and heart. However, only a low amount of POP
protein was detected in the liver (Fig. 5A, Fig. 5B).
5.1.2 Enzyme activity assay
In the enzyme activity measurements (Fig. 5A), the highest POP activity (pmol/min
* mg tissue) was located in the liver followed by testis. The activity was moderate in the
heart, lungs, thymus and brain. Lower levels of activities were measured from the
urinary bladder, adrenal gland and kidney. Surprisingly, the lowest activities were
assayed in the kidney although this organ contained almost the highest amount of POP
protein, and a high activity was measured from liver regardless of its small protein
amount. Moreover, the enzyme activity in the brain was only moderate despite the fact
that it contained highest protein amount. Generally, the POP enzyme activities in
various organs differed clearly from the POP protein distribution measured from the
whole-body immunohistochemistry (Fig. 5A).
5.2 Cellular and subcellular distribution of POP protein (I-II)
5.2.1 Cellular distribution of POP in mouse tissues
POP was generally widely present in various cell types, both in their nuclei and
cytoplasm. With respect to the liver, POP was moderately present in the cytoplasm and
the nucleus of the liver hepatocytes and nuclei of the Kupffer's cells (Fig. 4A-B in I).
POP was also present in the hepatic endothelial cells (Fig. 4B in I).  In the lungs, a
substantial amount of POP protein was observed both in the cytoplasm and nuclei of
type I and type II cells of the alveolar walls. A substantial amount of POP protein was
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also found in the nuclei of smooth muscle cells in the wall of the bronchioles (Fig. 4C-F
in I).
In kidney, high POP-immunoreactivity was observed in the medulla and it was less
abundant in the cortex (Fig. 5C). From moderate to high degree POP-immunoreactivity
was present in the glomerular podocytes (Fig. 5C) and the walls of tubules, but only
minor expression was found in the rest of the cortical labyrinth (Fig. 5C). In medulla,
POP was clearly present in the cells of walls of the tubules (Fig. 5C in I)
In the adrenal glands, POP immunoreactivity was high both in the cortex and
medulla (Fig. 5A in I). In particular, cells in the zona glomerulosa and zona reticularis
were intensively immunostained (Fig. 5E in I). In the cortex, POP was preferentially
present in the nuclei, whereas in the medullary chromaffin cells, POP was present both
in the nuclei and cytoplasm (Fig. 5F in I). In the heart, POP was moderately present in
the nuclei and sarcomeres of the cardiac muscle.
In the testis, POP was amply present in the nuclei of Sertoli cells of lamina propria,
spermatogonia and spermatocytes (Fig. 5D). Moderate POP immunoreactivity was seen
in developing spermatids, but not in the mature spermatids (Fig. 5D). Moderate amounts
of POP protein were observed in the thymus, both in cortex and medulla. POP was also
present in the nuclei of various types of epithelioreticular cells. POP was intensively
present in the nuclei and cytosol of the epithelium cells of the urinary bladder (Fig. 5E-
H). Moderate POP-immunoreactivity was seen in the connective tissue (Fig. 7A-B in I)
but only sparse staining was observed in the smooth muscle cells (Fig. 7A in I).
5.2.1.1 Nuclear POP in peripheral tissues and cell proliferation marker
We used triple-label immunofluorescence of POP, DAPI (a nuclear marker) and Ki-
67 (a proliferation marker) to determine whether the presence of POP in the nuclei is
associated with cell proliferation in peripheral cells. A rather poor colocalization
between POP, DAPI and Ki-67 was seen (Fig. 5E-H) despite the abundant
colocalization of POP and DAPI (Fig. 5E-H). The colocalization between cytosolic POP
and Ki-67 was moderate, (Fig. 8 in I) pointing to a possible role of POP in the cell
proliferation.
In order to substantiate the significant nuclear localization of the POP protein in the
peripheral tissues, in contrast to the brains, where no nuclear localization was seen, this
finding was confirmed by a western blot assay of POP protein from nuclear and
cytosolic fractions of the brain, liver, kidney and testis (Fig. 9 in I). In peripheral
tissues, POP was present also in the nuclear fraction while in the brain nuclear POP was
not seen. However, excluding the liver, the expression of POP protein was significantly
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smaller in the nuclear than in the cytoplasmic fraction, indicating that POP is preferably
present in the cytoplasm even in the peripheral tissues. The identity of nuclear and
cytoplasmic fractions was confirmed by nuclear (Histone H3) and cytoplasmic markers
(tubulin) (Fig. 9 in I).
Figure 5A-H. The distribution of POP in the peripheral tissues, determined by
immunohistochemistry from mouse whole-body sections (A, B) and enzyme activity
measurements (A). OD value of brain is set as 100% and other values are compared to
that value. Enzymatic activity is presented as pmol/min * mg tissue. Color codes in B
are similar to Fig. 4. In the photomicrographs, nuclei are blue, POP is visualized brown
and the colocalization gives dark blue/brown color. In the cortex of kidneys (C), POP
was present in the walls of tubules (Tub) and in the glomerulus podocyte cells (small
view, black arrows). Rather intensive POP immunostaining was seen in the testis
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spermatocytes (Sc) and in the Sertoli nuclei (Sn) (D). POP was moderately present in
the immature spermatids (Sp), but not in the mature spermatids (black arrowheads, D).
In Fig. E-F, triple-labeled immunofluorescence photomicrographs illustrating the
colocalization between POP (green), DAPI (blue) and Ki-67 (red) in the urinary bladder
epithelial cells. Photomicrographs are merged and the colocalizations of POP, DAPI
and Ki-67, in the same cells are pointed with white arrows. The abundant colocalization
of POP and DAPI is presented with white arrowheads. Scale bars: C, D, 20 µm; E-H, 10
µm.
5.2.2 POP distribution in the human brain (II)
In humans, POP was expressed quite evenly and widely in all analyzed brain areas
(optical density analysis, Fig. 6A). Generally, POP was present in the gray matter while
axons devoid the POP immunoreactivity (Fig. 6B). The expression of POP was the
highest in caudate nucleus followed closely by putamen and overall, POP was
extensively present in nigrostriatal pathway. However, POP was only moderately
present in red nucleus (Fig. 6B).
There was intense expression of POP in cerebellum. Immunostaining was clearly
evident in the cortex, especially in molecular cell layer and Purkinje cells, but only to a
moderate degree in the granular cell layer (Fig. 6B).
POP was very evenly and extensively present in all cortical areas, especially in
insular cortex (Fig. 6B). A large amount of POP protein was present in claustrum (Fig.
6B). Furthermore, POP was intensively immunostained in all parts of hippocampus
(Fig. 6B).
Lateral and medial geniculate bodies along with superior colliculus were
immunostained very intensively. Somewhat lesser degree of expression of POP was
observed in tegmentum (Fig. 6A).
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Figure 6A-B. The distribution pattern of POP in human brain (A). The optical density
(OD) values of analyzed brain areas are compared to corpus callosum OD value (set as
1). The color coded (from low levels = blue color or cooler to high levels = red tones or
warmer) image depicts the distribution of POP in horizontal human left whole-
hemisphere (B). Cb, cerebellum; CC, corpus callosum; Cd, caudate; Cing, cingulate
cortex; Cl, claustrum; Fr, frontal cortex; Hc, hippocampus; Ins, insular cortex; Occ,
occipital gyrus; Put, putamen; RN, red nucleus; SN, substantia nigra; T, temporal gyrus.
5.2.3 POP distribution in the rat brain (II, III)
The overall distribution of immunoreactive POP in the rat brain areas is presented
in Fig. 7A and Table 5.
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Cerebral cortex and forebrain
The intensity of POP staining was high in most of the regions of the cerebral
cortex, especially in motor, primary auditory, primary visual, granular insular and
somatosensory cortices (II). Generally, the staining was particularly intense in the large
and medium sized pyramidal cells and apical dendrites of layers II-VI (Fig. 7B). POP
immunoreactivity was also very visible in the piriform cortex. POP immunoreactive
neurons were moderately present in retrosplenial, lateral entorhinal and agranular
insular cortices in the large and medium sized pyramidal cells in layers III and V,
especially in the retrosplenial cortex (Fig. 1F in III).  Prelimbic, infralimbic and
cingulated cortices were less immunostained and the expression of POP was apparent
mostly in the pyramidal cells in layers II-III and V (Fig. 1G in III).
In striatum, POP was clearly visible in small to medium sized spiny neurons while
leaving myelin sheathed axons unstained (Fig. 7C). The spiny neurons of ventral
pallidum were also extensively immunostained with POP. A medium degree of POP-
immunostaining was present in the small to medium sized spiny neurons of nucleus
accumbens core and shell region of this brain site, while the POP level was slightly
lower in the nucleus accumbens core section (Fig. 7A).
In hippocampus, a high level of POP was seen in the pyramidal neurons and apical
dendrites descending to the stratum lacunosum moleculare in CA1 field (Fig. 7D).
Other parts of hippocampus (CA2, CA3, dentate gyrus and subiculum) were
immunostained with POP only from a moderate to a low degree (Fig. 7D). Furthermore,
in the areas with close connections to the hippocampus such as indusium griseum, POP-
immunoreactivity was particularly rich in the pyramidal neurons. POP was abundant in
somatospiny LS IIb neurons of the medial part of lateral septal area (Fig. 5 in III),
whereas in medial septum, no POP immunoreactivity was observed.
Midbrain
The highest POP densities in rat brain were measured from substantia nigra (Fig.
7A,E). The reticular and compact parts of the substantia nigra were intensively
immunostained, especially in the dendrites (Fig. 7E). Other midbrain nuclei such as
ventral tegmental area, superior and inferior colliculus were devoid of POP
immunoreactivity.
59
Thalamus and hypothalamus
Moderate POP staining was found in different thalamic nuclei, such as the
ventroposterior nucleus group, posterior nucleus group, laterodorsal nuclei (Fig. 7 in
III), mediodorsal thalamic nucleus and ventromedial thalamic nucleus. Similar to
human, in lateral and medial geniculate nucleus (Fig. 7A), the expression of POP was
high.
In the hypothalamus, practically no POP was detected with the exception of the
medial mamillary nucleus where a moderate level of POP was observed (Fig. 7A).
Cerebellum, pons and medulla
In the cerebellum, the expression of POP was high in the cortex and in the
Purkinje's cells which were intensively immunostained both in somas and in dendrites
of the molecular cell layer (Fig. 7F). The granular cell layer virtually lacked POP
immunoreactive cells (Fig. 7F). POP was not present in pons and medulla oblongata and
in the myelin sheathed axon bundles such as corpus callosum (Fig. 7A) and anterior
commissure.
POP and astrocytes
Localization of POP in astrocytes was studied using double-staining
immunofluorescence and using glial fibrillary acid protein (GFAP) as a glial marker.
However, POP was not detected in astrocytes in any of the sections made throughout
the brain (Fig. 9H).
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Figure 7A-F. The distribution of immunoreactive POP in the rat brain. The optical
density (A) values of analyzed brain areas are compared to corpus callosum OD value
(set as 1). In the somatosensory cortex layers V and VI (B), POP was intensely present
in the pyramidal cells somas (black arrow) and dendrites (white arrows). High POP
immunoreactivity was seen in the spiny neurons of striatum (C, black arrows) and CA1
field of hippocampus (D). Substantia nigra (E) was abundantly immunoreactive for
POP similar to Purkinje cells (F) of the cerebellum. CA1, CA2, CA3, hippocampal CA
fields; DG, dentate gyrus; Gran, granular cell layer of cerebellum; Mol molecular cell
layer; P, Purkinje cell; Sn, substantia nigra. Scale bars: B,C, 30 µm; D, 50 µm; E, 150
µm; F, 10 µm.
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5.2.4 Subcellular localization of POP in the rat brain
In post-embedding immunoelectron microscopy, POP was identified using 15 nm
fully round gold particles coupled to the secondary antibody. We studied rat brain tissue
samples from those areas where POP immunoreactivity was clearly visible i.e. striatum,
primary somatosensory cortex, Purkinje’s cells, substantia nigra and the CA1 area of
hippocampus.
The enzyme was generally and most abundantly found freely-moving in the
cytoplasm (Fig. 8A). However, POP seemed also to be attached to cell membranes (Fig.
8B), especially to the intracellular membranes of rough endoplasmic reticulum (RER,
Fig. 8C) and Golgi apparatus (Fig. 8D). Some POP was also found inside the axons
(Fig. 10F in III) and within their myelin sheaths (Fig. 10F in III).
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Figure 8A-D. High magnification electron photomicrographs depicting subcellular
distribution of POP in rat brain. POP was present freely in cytoplasm (A, black arrows
point to the 15 nm gold particles, white arrow points to the immunoreactive POP in the
rough endoplasmic reticulum, rer) and in the cell membranes (B, small view is a
magnification from the larger picture, white arrows indicate POP in the cell membrane
and n marks the nucleus). POP was present in the membrane of RER (C, black arrow)
and Golgi apparatus (g) (D, small view is a magnification from the larger picture, black
arrows indicate POP in the Golgi, n points to the nucleus). Scale bars: A, 0.1 µm; B, 50
nm; C, 0.2 µm; D, 0.1 µm.
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5.3 Spatial associations of POP protein with specific neurotransmitters and its
presumed substrates in the rat brain (III, IV)
Double-label immunofluorescence of POP with GABA (III), ACh (III), SP (IV)
and its NK1-receptor (NK1R) and IP3 type 1 receptor (IP3R1) (IV) was evaluated
throughout the whole rat brain and the percentages of colocalizations are shown in
Table 5. Furthermore, the colocalization of POP with a dopamine marker in the
nigrostriatal path was studied by double-label immunofluorescence and specific
lesioning of dopaminergic neurons (III).
5.3.1 GABA, ACh and dopamine (III)
In addition to the pyramidal cells (see section 5.2.3), which are known to be highly
glutaminergic, POP was also present in the cerebral cortex in large and medium sized
GABAergic (Fig. 2A-C in III) and cholinergic (Fig. 2G-I in III) interneurons (Table 5).
In striatum and nigrostriatal path nuclei, POP-immunoreactive neurons were mostly
GABAergic (Fig. 9A, Table 5) and colocalization with cholinergic neurons was poor
(Table 5). Interestingly, both double-label immunofluorescence and neuronal
morphology indicated that, POP was not present in TH-containing dopaminergic cells in
striatum (Fig. 3D in III). In confirmation, lesioning of nigrostriatal dopaminergic
neurons using 6-OHDA, removed tyrosine hydroxylase (TH) reactive dopaminergic
neurons from striatum while leaving the POP-containing cells intact (Fig. 3E-J in III).
The pyramidal neurons of hippocampus CA1 containing POP were seldom
GABAergic or cholinergic (Fig. 4C-D in III, Table 5), whereas in indusium griseum,
POP immunoreactive neurons were usually GABAergic (Fig 4E in III, Table 5). POP-
immunoreactive neurons of lateral septal area were GABAergic and no colocalization
between POP and ChAT was observed (Fig 5B-D in III, Table 5).
Thalamic POP was quite evenly present in GABAergic (Fig. 8B-D in III) and
cholinergic medium sized projection neurons (Fig. 8E-G in III, Table 5)
In the cerebellar Purkinje's cells, there was clear colocalization with the
GABAergic marker (Fig.9B, Table 5).
5.3.2 POP and IP3R1 (IV)
In the cerebral cortex, we found moderate to substantial POP colocalization with
IP3R1 (Fig. 1A-F in IV), the percentages in the cerebral cortex varying from 31%
(primary visual cortex) to 63% (piriform cortex, Table 5).
64
In the high POP-immunoreactive nuclei in nigrostriatal path, such as striatum (Fig.
2A-C in IV), lateral globus pallidus and substantia nigra, generally a low degree of
colocalization of POP and IP3R1 was observed (Table 5).
In POP-immunoreactive hippocampal areas, such as CA1, CA2 and CA3, POP was
highly colocalized with IP3R1 containing pyramidal cells (Fig. 9C, Table 5). In the
lateral septum (Fig. 3D-F in IV), POP colocalization was only 34% (Table 5).
The colocalization of POP and IP3R1 in the thalamus was extremely high. In the
middle section of thalamus, where POP is abundantly present in neurons, the percentage
of colocalization varied from 66 to 86% (Fig. 9D, Table 5).
In cerebellum, the colocalization of POP and IP3R1 was 77% in the Purkinje cells
and molecular layer (Fig. 5A-C in IV).
5.3.3 POP and SP (IV)
The colocalization between POP and SP was generally rather low throughout the
brain. POP was weakly colocalized with SP-immunoreactive neurons (Table 5). In
cerebral cortex (Fig. 9E, Table 5), the degree of colocalization varied from 20%
(agranular insular cortex) to 39% (auditory cortex). Similar minor coexpression was true
also in forebrain nuclei, such as striatum (Fig. 7A-C in IV), lateral globus pallidus and
nucleus accumbens, areas which contain high amounts of POP protein (Table 5).
In hippocampal CA-fields (Fig. 8F) and in the lateral septum (Fig. 8D-F in IV), the
coexpression was rather weak (Table 5). The colocalization was also poor throughout
the thalamus, as well as in the midbrain nucleus and substantia nigra, both regions rich
in POP protein (Table 5).
In cerebellum, POP and SP were abundantly colocalized in the Purkinje cells but
less extensively in the molecular layer (Fig. 9A-C in IV).
5.3.4 POP, GABAergic cells and SP (IV)
We also studied the coexpression of POP, GABAergic cells and SP in the rat
striatum and motor cortex using triple-label immunofluorescence. In the striatum, 26 ±
2% (average ± SEM) of those GABAergic cells having POP-immunoreactivity
contained also SP (Fig. 10A-D in IV). About 65 % of GABAergic cells in the striatum
contain POP (Table 5) and therefore we detected a significant population of GABAergic
and POP-immunoreactive cells without SP, as well as POP-containing cells with SP, but
no GABA (Fig. 10D in IV). In cortex, the mutual cellular localization of POP, GABA
and SP was less impressive (19 ± 5%, when compared to POP-containing cells) than in
the striatum (Fig. 10E-H in IV).
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5.3.5 POP and NK-1R (IV)
Double-label immunofluorescence between POP and SP receptor, NK-1R, was
made throughout the rat brain. However, virtually no colocalization of these proteins
was observed (Fig. 9G). The size and shape of NK-1R positive cells clearly differed
from POP immunoreactive cells and only in a few areas (Fig. 11I in IV) were the
projections of NK-1R positive cells in the vicinity of POP containing cells.
Figure 9A-H. Confocal (A-C, F-G) and fluorescent (D-E, H) photomicrographs
presenting the high colocalization of POP with GAD 65/67 (GABA-marker) in striatum
(A) and cerebellar Purkinje cells (B), and with IP3R1 in hippocampal CA1 field (C) and
thalamus (D). Poor colocalization is seen with POP and SP in cortex (E) and
hippocampal CA1 (F), and with NK1R (G) and astroglial markers (GFAP, H) in the
cortex. POP is presented in green color, other substance in magenta and the
colocalization is visualized as white color and white arrows. Scale bars A-C,F-G, 6 µm;
D-E,H, 20 µm.
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Table 5. The distribution of POP immunoreactivity in the rat brain and its
colocalizations with GABAergic (GAD 65/67), cholinergic (ChAT), IP3R1 and SP
markers. The colocalization percentage is calculated comparing the GABA, Ach, IP3R1
and SP immunoreactive neurons with POP-immunoreactive neurons.
Structure Expression
of POP
Colocalization of
POP with GAD
65/67
(%)*
Colocalization of
POP with ChAT
(%)*
Co-
localization
of POP with
IP3R1
(%)*
Co-
localization
of POP with
SP
(%)*
Forebrain and cerebral
cortex
Agranular insular
cortex
++ 58 ± 2.6 42 ± 3.1 58 ± 4.7 20 ± 3.5
Auditory cortex,
primary
+++ 37 ± 4.4 41 ± 2.9 46 ± 5.7 39 ± 2.9
Cingulated cortex + 23 ± 1.7 31 ± 3.9 42 ± 3.8 31 ± 5.6
Granular insular
cortex
+++ 34 ± 2.2 36 ± 2.0 47 ± 2.8 33 ± 3.5
Infralimbic cortex + 50 ± 4.7 38 ± 3.3 53 ± 2.4 27 ± 2.5
Lateral entorhinal
cortex
++ 45 ± 4.0 36 ± 3.3 57 ± 1.0 35 ± 2.7
Motor cortex,
primary
layer 1
layer 2
layer 3
layer 4
layer 5
layer 6
0
++
+++
++
+++
+++
-
54 ± 4.9
50 ± 2.4
43 ± 1.4
35 ± 4.2
45 ± 5.3
-
21 ± 2.8
32 ± 2.5
30 ± 7.0
37 ± 3.3
40 ± 2.7
-
56 ± 1.5
31 ± 2.9
35 ± 1.5
40 ± 2.5
37 ± 2.5
-
29 ± 4.8
35 ± 3.8
34 ± 0.5
35 ± 2.3
22 ± 2.9
Piriform cortex +++ 43 ± 3.6 53 ± 3.4 63 ± 9.8 25 ± 1.2
Prelimbic cortex + 34 ± 4.7 38 ± 3.4 52 ± 2.1 35 ± 4.8
Retrosplenial
cortex
++ 46 ± 2.7 57 ± 4.6 38 ± 4.2 25 ± 5.6
Somatosensory
cortex, primary
layer 1
layer 2
layer 3
layer 4
layer 5
layer 6
0
+++
+++
++
+++
+++
-
37 ± 1.5
43 ± 6.7
37 ± 4.4
42 ± 2.3
44 ± 5.6
-
33 ± 5.6
39 ± 4.2
38 ± 1.7
36 ± 3.8
39 ± 2.8
-
40 ± 7.1
32 ± 4.3
53 ± 6.4
54 ± 7.0
57 ± 2.8
-
24 ± 1.9
28 ± 1.1
29 ± 3.6
38 ± 3.0
39 ± 6.4
Visual cortex,
primary
++ 35 ± 3.4 28 ± 3.6 31 ± 2.3 33 ± 1.9
Claustrum +++ 43 ± 3.3 44 ± 6.4 51 ± 4.8 26 ± 3.4
Lateral globus
pallidus
++ 44 ± 2.3 26 ± 1.8 38 ± 2.7 30 ± 4.5
Striatum +++ 61 ± 2.9 29 ± 3.2 36 ± 5.2 26 ± 2.2
Ventral pallidum +++ 45 ± 2.9 28 ± 3.6 59 ± 7.9 29 ± 6.1
Nucleus accumbens
core
shell
++
+
37 ± 3.2
32 ± 3.1
42 ± 4.9
45 ± 3.3
38 ± 3.0
42 ± 2.3
31 ± 2.8
35 ± 1.5
Hippocampus
CA1
CA2
CA3
dentate gyrus
+++
++
++
+
27 ± 2.1
25 ± 2.2
23 ± 3.4
31 ± 3.7
29 ± 4.3
26 ± 3.6
87 ± 7.6
83 ± 3.3
87 ± 4.6
27 ± 2.9
28 ± 4.3
26 ± 3.2
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stratum
laconosum
+++
Indusium griseum ++ 55 ± 4.1 26 ± 2.5 - -
Lateral septal area +++ 36 ± 7.0 - 34 ± 4.5 21 ± 4.7
Medial septum 0
Nucleus basalis
mangocellularis
0
Diagonal band of
Broca
0
Midbrain
Substantia nigra ++ 58 ± 3.5 27 ± 4.4 25 ± 4.1 23 ± 2.9
Ventral tegmental
area
0
Red nucleus 0
Superior colliculus 0
Inferior colliculus 0
Thalamus and
hypothalamus
Ventroposterior
nuclei
++ 43 ± 3.9 34 ± 5.2 78 ± 3.9 32 ± 3.5
Posterior thalamic
nuclear group
++ 46 ± 2.4 43 ± 2.5 86 ± 4.3 40 ± 3.8
Laterodorsal
thalamic nucleus
++ 42 ± 2.4 34 ± 3.2 85 ± 3.5 32 ± 3.7
Mediodorsal
thalamic nucleus
++ 45 ± 6.4 35 ± 2.6 83 ± 1.6 35 ± 3.6
Ventromedial
thalamic nucleus
++ 42 ± 4.9 34 ± 1.5 66 ± 7.2 38 ± 6.6
Medial geniculate
nucleus
++ 38 ± 5.2 34 ± 1.9 71 ± 6.6 25 ± 4.6
Lateral geniculate
nucleus
++ 49 ± 5.5 35 ± 3.3 44 ± 7.4 30 ± 2.2
Medial mammillary
nucleus
+
Cerebellum and pons
Cerebellum
Purkinje cells
and molecular
layer
Granular layer
+++
0
90 ± 3.7 - 77 ± 5.8 45 ± 6.1
Medulla 0
The densities of POP immunoreactive cells in brain structures: 0, no POP
immunoreactivity; +, low density of POP; ++, moderate density of POP; +++, high
density of POP; - (not detectable); * Mean ± SEM
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6 DISCUSSION
6.1. Whole-body distribution of POP protein and POP activity (I)
We have studied comprehensively the distribution of the immunoreactive POP
protein in mouse peripheral tissues and in rat and human brain. Our whole-body
immunohistochemistry revealed that the POP protein is widely, but still specifically,
distributed in peripheral tissues. Based on the enzyme activity studies conducted in rats
(Daly et al. 1985, Fuse et al. 1990, Irazusta et al. 2002, Agirregoitia et al. 2005), there
has been a belief that the highest amounts of POP are located in the brain, although the
results have not been unanimous (see section 2.3.1.1). Here we have demonstrated that
the POP protein is equally abundantly present in the mouse brain, kidney, testis and
thymus, but much less in the liver.  Moreover, the enzymatic activity of POP differed
significantly from the relative amounts of POP protein, both in the brain and peripheral
tissues.
In the mouse high-throughput gene expression measurements (GNF SymAtlas, Su
et al. 2002), highest peripheral POP mRNA has been generally found from the thymus,
followed by the lungs and adrenal gland. Interestingly, in the rest of the analyzed
tissues, the amounts of POP mRNA were rather equal. The distribution of POP mRNA
in mouse peripheral tissues was partially similar with POP protein, since rather high
amounts of POP protein were determined from the lungs and thymus. However, some
differences also occurred. We found the highest amounts of POP protein in the kidney,
while POP mRNA was only moderately present in that tissue.
This raises an interesting question concerning the regulation of POP activity and
protein. Endogenous POP inhibitor (Yoshimoto et al. 1982, Salers 1994, Yamakawa et
al. 1994) may influence to the different localization between POP protein and activity,
although its function and mechanism are still poorly characterized. One rationalization
might be the regulation of POP enzymatic activity via its substrate expression.
However, uneven distribution of POP substrates, e.g. SP, TRH and AVP, in the brain
and peripheral tissues explains only partially the distribution of POP protein or POP
activity (see chapters 2.3.1.2 and 2.3.2.4). As a further support, spatial locations of POP
protein and SP are poor - at least in the rat brain - pointing to the fact that the locations
of POP with its presumed substrates are not identical or even adjacent in vivo meaning
that direct hydrolysis seems unlikely. Somewhat different distribution of POP mRNA
and POP protein in certain peripheral tissues may occur from different methods, but
post-translational modification or protein trafficking is a conceivable possibility.
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This discrepancy between the density of POP protein and its enzymatic activity is
interesting, and points to a strict endogenous regulation of POP.  Furthermore, the
presence of POP in specific internal organs supports some role for POP in these tissues,
although actions of peripheral POP are still unclear and conclusions of the physiological
role of POP in peripheral tissues cannot be drawn based on our findings.
6.2 Cellular and subcellular distribution of POP protein (I-III)
6.2.1 POP in peripheral organs of mouse (I)
In peripheral tissues, POP protein was present in various cell types of different
organs, excluding cell-type specificity. However, most importantly, we observed in our
immunohistochemical and western blot studies that POP was generally present also in
the nuclei of the peripheral tissue cells. Generally, also in the brain tissue, POP has been
considered as a cytosolic enzyme but a membrane-bound form has been reported
(Dresdner et al. 1982, O'Leary et al. 1995, Schulz et al. 2005, Garcia-Horsman et al.
2007a). POP protein and enzymatic activity have been detected in the nucleus of the
nonneuronal cell lines (Ishino et al. 1998), but probably also in neuronal cell cultures
early in development (Moreno-Baylach, Felipo, Männistö and Garcia-Horsman,
unpublished results 2007). This is in contrast to the brain where we were not able to
detect any POP protein in the nuclei (III, IV) and it may be important when defining the
physiological role of POP (see section 6.4).
6.2.2 POP in the rat and human brain (II-III)
In the rat and human brain tissue, POP has been previously localized by measuring
enzyme activities (Kato et al. 1980b, Fuse et al. 1990, Goossens et al. 1996, Gallegos et
al. 1999, Irazusta et al. 2002, Agirregoitia et al. 2003b, Agirregoitia et al. 2005) and
POP coding mRNA levels by in situ hybridization (Bellemere et al. 2004). Interestingly,
based on the results in the literature, POP activity significantly differed from the amount
of the POP protein also in the brain tissues (for references, see sections 6.1 and 6.4).
Moreover, the distribution of POP protein in our studies and POP coding mRNA
(Bellemere et al. 2004) in the brain were considerably different. For example, POP
mRNA was present in high amounts in the hypothalamus (Bellemere et al. 2004), where
POP substrates, such as TRH and AVP are also located (see chapter 2.3.2.4). However,
we failed to determine immunoreactive POP protein in the hypothalamus, with the
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exception of medial mammillary nucleus where minor amount of POP protein was seen.
A similar discrepancy between the expression of POP mRNA and POP protein was
observed also from substantia nigra and various other brain areas. In the rat GNF
SymAtlas (Su et al. 2002), similar to the POP protein distribution, the highest POP
mRNA amounts were found from the hippocampus followed by the frontal cortex and
dorsal striatum. However, also in this databank equal amounts of POP mRNA were
found from the cerebral cortex, hypothalamus and locus coeruleus even though we did
not observe any POP protein in the hypothalamus or locus coeruleus. Although there are
some differences between high-throughput gene expression measurements and in situ
hybridization of POP mRNA (Bellemere et al. 2004), discrepancy between POP protein
and POP mRNA occurs. These differences may be due to posttranslational modification
of POP or differential targeting and/or mRNA turnover regulation. It still remains
unclear how the POP enzyme is transported from these synthesis sites to the protein
expression areas. Sequence analysis of POP protein and its gene indicates that this
enzyme is cytosolic but it has not revealed any potential sites for post-translational
modification or trafficking signal sequences nor is there any promoter signal which
would point to the transport or modulation of the protein (Venäläinen et al. 2004).
The specific functions of the brain areas rich in POP may offer some explanations
for the role of POP in the CNS. The high or moderate POP levels in the nigrostriatal
systems of both rat and human, specifically in substantia nigra, globus pallidus, ventral
pallidum and caudate putamen may point to a role for POP in motor functions (Paxinos
1990, Paxinos 2004) and indeed fluctuations of POP activity have been reported in the
Parkinson's disease (Mantle et al. 1996). Furthermore, the high expression of POP in
cerebellar Purkinje cells, pyramidal cells of motor cortex and projecting areas of the
thalamus also postulates involvement of POP in the control of movements (Thach et al.
1992, Paxinos 2004).
Moreover, POP has been generally associated with the cognitive functions
(Männistö et al. 2007). The occurrence of POP in human and rat hippocampus,
particularly in the CA1 field pyramidal neurons, is evidence of some potential
modulation of limbic activity (Paxinos 1990, Paxinos 2004). POP-immunoreactivity
was also high in several other areas believed to participate in cognitive functions, such
as the lateral septum and indusium griseum (Paxinos 2004). This indicates that POP
may actively participate in CA1 neurotransmission to subiculum and to deep layers IV-
VI of the entorhinal cortex (Amaral 1993, Paxinos 2004), and to the lateral septum as
well (van Groen et al. 1990). However, POP was present only to a moderate extent in
the prefrontal cortex, lateral entorhinal cortex and nucleus accumbens, other areas
associated with the memory and learning functions (Paxinos 2004).
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The abundant presence of POP in the projection neurons of sensory motoric areas
of the cerebral cortex (i.e. motor and sensory cortices, gustatory cortex, visual and
auditory cortices) and the corresponding projection areas of the thalamus may hint at its
physiological role. POP expressing projecting pyramidal cells were detected especially
in layers V and VI of the somatosensory and motor cortex and these cells are known to
have strong afferent connections to the POP immunoreactive thalamic nuclei, such as
ventral posterolateral and -medial nuclei (Paxinos 2004). These results suggest that POP
may be involved in the regulation of thalamocortical neurotransmission in several
thalamocortical loops, possibly as a regulator of neuropeptide levels or some other
regulatory function. Further support for the role of POP in the regulation of
neurotransmission may come from the abundant expression of protein in the cerebellar
Purkinje cells that are known to be the major output cells of the cerebellum (Thach et al.
1992, Braitenberg et al. 1997).
Our study revealed, that POP was not located in the astrocytes in any part of the rat
brain studied. This finding is in contrast to POP activity measurements performed with
the cell lines in vitro, where enzyme activities have been found both in neuronal and
glial cells (Koshiya et al. 1984, Mentlein et al. 1990, Schulz et al. 2005) but agrees with
the study in which POP was found exclusively in neurons of both adult and aged mouse
neurons and as well as human Alzeimer’s diseased brains (Rossner et al. 2005).
Furthermore, in the study of Bellemere et al. (2004), the POP coding mRNA was not
present in the astrocytes. However, we were able to locate small amounts of POP
protein in the myelin sheaths using electron microscopy and some enzyme activities
have also been detected from oligodendrocytes (Koshiya et al. 1984). The reason for
this discrepancy of the astroglial expression between in vitro and in vivo results may
derive from the different localization – and probably different functions as well – of
POP in the proliferating tissues, such as peripheral tissues and cell cultures (see section
6.4).
6.2.3 Subcellular localization of POP in the rat brain (III)
The subcellular localization of POP supports the proposed role of POP in peptide
and protein trafficking, processing and secretion (Schulz et al. 2005, Garcia-Horsman et
al. 2007a). We found that POP was associated with the Golgi apparatus and rough
endoplasmic reticulum (RER) membranes, well known organelles where protein
processing and secretion occurs. Using confocal microscopy, Schulz et al. (2005) found
that POP was attached to the microtubules, i.e. a cytoskeletal component. We did not
detect the POP protein in the microtubules. However, due to the fixatives required for
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electron microscopy immunohistochemistry, we may have overlooked the presence of
POP in microtubules in vivo. Nevertheless, the localization of POP in the Golgi
apparatus and RER may point to a function for POP as participating in processing the
immature form of proteins, possibly even its substrates, such as SP and TRH.
As anticipated, the majority of POP was present free in the cytosol (Dresdner et al.
1982, Polgar 1994). The cytosolic form may participate in the cleavage of proline-
containing peptides being co-localized with POP, and evidently also acts as a regulator
of IP3-signalling while IP3 itself is not a substrate of POP (Williams et al. 2000,
Williams et al. 2002). The presence of POP in the intracellular RER also may point to a
role for POP in IP3-signalling, since IP3 type 1-receptors reside in the RER membranes
(Vermassen et al. 2004).
Some POP was found also in the cell and cytoplasmic membranes. Even though
there is some evidence for a membrane-bound POP activity (O'Leary et al. 1995), the
identity of this enzyme has not been conclusively confirmed. Furthermore, POP in the
RER was also attached to the intracellular membranes, and it is not known whether this
POP is the membrane-bound or cytosolic form of POP.
6.3 Spatial associations of POP with specific neuronal neurotransmitters and its
substrates (III, IV)
Since the associations between POP and neuronal neurotransmitters are unknown,
we considered it important to study this matter. Since POP is mainly an intracellular
enzyme, it may participate in the neurotransmission via an intracrine mechanism (Re et
al. 2006). Furthermore, there is an abundance of data for an intracellular colocalization
of neuropeptides with classic neurotransmitters like ACh, GABA, histamine and
catecholamines.
Cortical GABAergic interneurons contain several neuropeptides, such as SP and
somatostatin, both potential POP substrates (Table 1, Emson et al. 1979, Kawaguchi et
al. 2002, Garcia-Horsman et al. 2007a) and the colocalization of POP with GABA in the
cerebral cortex was rather rich. However, only a poor degree of colocalization with POP
and SP was seen in the cerebral cortex and the coexpression of POP, SP and GABA
among the POP containing cells was only 19%. Therefore, due to the poor spatial
colocalization of POP and SP, it seems unlikely that POP is involved to any significant
extent in SP-mediated neurotransmission in the cerebral cortex or at least an effective
transport system for SP and/or POP itself is needed.
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Moreover, in striatum POP was present to a major extent in the GABAergic
neurons but not in the TH-immunoreactive dopaminergic neurons and hardly at all in
the cholinergic neurons, pointing to a role of POP in the inhibitory regulation of
nigrostriatal path (Paxinos 2004). Interestingly, GABAergic neurons which are rich in
POP protein, do use SP as a neurotransmitter (Besson et al. 1990, McGinty 2007). SP
also participates in the "direct pathway neurotransmission" by slowly modifying the
signalling activated after loss of dopaminergic input to the striatum, e.g. in Parkinson’s
disease. GABA is known to inhibit SP release and SP, on the other hand, releases AVP,
histamine and ACh (Skidgel et al. 2006, Standaert et al. 2006).  Therefore, we studied
the coexpression of POP, GABA and SP using triple-label immunofluorescence and
observed that in striatum, SP was present only in 26% of GABAergic POP-containing
cells. Furthermore, since it is known that SP rich GABAergic neurons are an integral
component of the neurotransmission in the direct nigrostriatal pathway (Paxinos 2004),
it seems likely – based on our results - that POP is more involved in the inhibitory
neurotransmission of the indirect nigrostriatal path than in the neurotransmission of
projection neurons in direct path.
In cerebellar Purkinje cells, POP was highly colocalized with GABA and IP3R1 and
also substantial colocalization of POP and SP was found in those cells. The presence of
IP3R1 in the Purkinje cells has been linked to cerebellar LTD (Khodakhah et al. 1997)
and the possible involvement of POP in the IP3-signalling (see above) may suggest a
role for POP also in the cerebellar LTD. SP is a regulator of cerebellar circuits since it
controls the firing of the Golgi cells and in this way can modulate the cellular activity of
Purkinje cells through parallel fibers (Inagaki et al. 1982, Del Fiacco et al. 1988,
Nakaya et al. 1994). Moreover, high colocalization of POP with GABA points to a role
as a regulator of the dominant GABAergic neurotransmission in the Purkinje cells.
These results may indicate a role for POP as a signal modulator in the cerebellar
Purkinje cells, possibly via the regulation of SP levels. However, it is not known how
POP is able to hydrolyze SP located inside the vesicles.
POP was partially colocalized with the brain cholinergic system (Table 5). The
associations of POP and ACh are poorly understood, but repeated administration of
POP inhibitors has increased M3-muscarinic receptor mRNA levels (Katsube et al.
1996) and ACh activity in the cortex of old rats (Toide et al. 1997). The mechanisms of
these kinds of actions are not known and blockade of neuropeptide cleavage, especially
TRH (Toide et al. 1993), is one possibility. However, the rather poor colocalization of
POP with ACh (Table 5) - especially in the cortex areas important for memory and
learning, such as lateral entorhinal cortex – is not support for the participation of POP in
ACh mediated memory and learning functions. As a further support, no POP
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immunoreactivity was observed in the medial septum, diagonal band of Broca and
nucleus basalis magnocellularis, the most important cholinergic memory and learning
areas projecting to the hippocampus and cortex (Paxinos, 2004).
The cortical spiny pyramidal cells, also neurones very rich in POP, are known to be
mostly glutamatergic (DeFelipe et al. 2002, Paxinos 2004). Furthermore, changes in
POP activity were recently observed in the rat cortex and hippocampus after
administration of an N-methyl-D-aspartate (NMDA)-antagonist to induce
schizophrenia-like symptoms (Ahmed et al. 2005, Arif et al. 2007). These findings
support the participation of POP in the glutamatergic neurotransmission in the brain -
possibly by modifying the levels of the POP substrates, such as TRH (Kasparov et al.
1994). Moreover, it is known that glutamatergic neurotransmission and changes in the
morphology of cortical pyramidal cells are associated with schizophrenia (Lewis et al.
2000, Lewis et al. 2003) and this may explain why there are changes in the activity of
serum POP which show a correlation with the severity of schizophrenic symptoms
(Maes et al. 1995). However, the variations of enzymatic activity of POP in plasma
should be looked with a doubt (see section 2.3.3).
In the hippocampus CA1 area, a brain region important for memory and learning,
based on the size and shape of the neurons and the results of colocalization studies, we
have shown that most of the cells containing POP in the hippocampus CA1 were
glutamatergic pyramidal cells (Van der Zee et al. 1997, Paxinos 2004) rather than
GABAergic or cholinergic interneurons. These results substantiate the findings where
single or repeated administration of the POP inhibitor, JTP-4819, did not affect the
hippocampal ACh levels (Toide et al. 1997). Furthermore, POP was highly colocalized
with IP3R1 in hippocampal CA1 pyramidal cells. In these cells, IP3 has been associated
with LTP and LTD, important phenomena in memory and learning this probably is due
to release of Ca2+ within the cell (Lynch et al. 1991, Bliss et al. 1993, Khodakhah et al.
1997, Jun et al. 1998, Fujii et al. 2004, Taufiq et al. 2005).  Interestingly, LTP is
induced by the activation of NMDA-glutamate receptors (Bliss et al. 1993, Fujii et al.
2004) and therefore, based on the proposed involvement of POP in IP3 signalling
(Williams et al. 2000, Schulz et al. 2002, Williams et al. 2002, Cheng et al. 2005) as
well as our findings, it appears likely – at least in spatial terms -  that POP may have a
role in IP3-mediated LTP regulation in hippocampal CA1. SP is also able to induce LTP
in the hippocampus, and NK1Rs are necessary for the mediation of this effect
(Langosch et al. 2005). However, the limited coexpression of POP with SP and NK1-
receptors points to POP acting in LTP through some other mechanism rather than
simple SP hydrolysis. Our studies suggest that the beneficial effects of POP inhibitors
on impaired memory and learning (Toide et al. 1995a, Toide et al. 1997, Schneider et al.
75
2002) may be a consequence of the elevation in the levels of IP3 and hence enhanced
LTP and LTD in the hippocampus.
Furthermore, the expression of IP3R1 in POP-immunoreactive cells was generally
modest in the cerebral cortex and subchronic administration of POP-inhibitors caused
no significant increase in the IP3 levels of cerebral cortex (Jalkanen et al. 2007). This is
most likely due to the fact that only a rather minor population of IP3R1-immunoreactive
cells contain also POP, and as a consequence no changes of IP3 levels could be seen in
the whole cortex homogenates after administration of POP-inhibitor
POP was equally present both in inhibitory and excitatory neurons in the thalamus
but the coexpression of POP with IP3R1 in thalamus was striking. IP3-signalling in the
thalamus has been rather poorly characterized, but it may be involved in the regulation
of thalamocortical rhythms (de la Vega et al. 1996) and the role of these oscillations in
epileptic seizures has been extensively documented (Miller et al. 1990a, Miller et al.
1990b, Gale 1992). VPA evidently modifies these spontaneous rhythms (Nowack et al.
1979, Mares et al. 1992, Zhang et al. 1996), although not via the GABAergic system
(Zhang et al. 1996). Interestingly, POP is inhibited by VPA and it is claimed to be a
direct target of this drug in vivo (Cheng et al. 2005). Collectively, high amounts of POP
protein in the thalamus support the involvement of POP in thalamocortical
neurotransmission, possibly through the regulation of IP3-signalling.
6.4. POP in cell proliferation/differentiation and future studies (I-IV)
The variations between the expression of POP in the brain, cell lines and peripheral
tissues (see sections 6.2.1 and 6.2.2) may depend on differences in cell proliferation. It
is well known that the mature brain tissue is not proliferating, while peripheral tissues
and cell lines are continuously dividing. The nuclear colocalization of POP protein and
a cell proliferation marker Ki-67 (for review, see Scholzen et al. 2000) was only partial
but the colocalization of non-nuclear POP and Ki-67 was rather convincing. Since the
Ki-67 is absent from the cells only during the G0-phase, the proposed direct effect of
POP to the DNA synthesis in vitro (Ohtsuki et al. 1994, Ohtsuki et al. 1997b, Ishino et
al. 1998) seems questionable. However, the indirect participation of POP in DNA
synthesis may occur since we observed POP to be present in the cytoplasm of the cells
during the active phase of proliferation. Furthermore, our studies may support a role in
the cell division and/or differentiation since POP activity is also high early in the
development (Matsubara et al. 1998, Agirregoitia et al. 2003a, Agirregoitia et al. 2007)
and in the cancer cells (Goossens et al. 1996). High POP activities were seen in the
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testis where the POP protein was exclusively present in the developing spermatids,
supporting the results obtained by Kimura et al. (2002) in mouse testis.
Consequently, in proliferating tissues, such as peripheral tissues and immortal cell
cultures, nuclear POP may have some novel roles, such as modification of nuclear
transport (Schulz et al. 2005, Puttonen et al. 2006) or other catalytic functions as a
prolyl cis-trans isomerization (Lu et al. 2007, Ikura et al. 2008). Furthermore, our
finding could explain the differences that were noted between neuronal cell culture
studies and mature brain tissue, such as POP activity expression in glial cell cultures
(see section 6.2.2).
However, more studies are needed to explore the nuclear functions of the POP
protein. The localization of POP during ontogenesis should be studied with primary cell
cultures and embryonic tissue in order to make conclusions about the physiological role
of POP in this period. Moreover, in order to achieve information concerning the POP
substrates in the nucleus, a microarray study using POP inhibitors should be executed.
To study the role of POP in the cell proliferation/differentiation, cancerous cell
lines/tissues should be used. There is also a need for more detailed co-localization study
between POP and its putative substrates, such as TRH and AVP, to clarify the spatial
possibilities of POP to degrade these substances. Furthermore, our hypothesis of POP as
a regulator of thalamocortical signaling should be studied using neuronal tracing and
functional studies with POP inhibitors.
 Collectively, some conclusions and hypothesis based on our present results and the
literature review are collected in Table 6.
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Table 6. Different POP locations and suggestions/hypothesis for their functions
Tissue Cell type Subcellular location Suggested functions
Brain Neurons Cytoplasm Polypeptide hydrolysis
IP3 synthesis
Microtubulus functions
Membranes of cell,
RER and Golgi
Polypeptide hydrolysis
Protein trafficking
Protein modification in trans-
Golgi network (?)
Extracellular hydrolysis (?)
Axons Axonal transport
Oligodendrocytes (?)
Peripheral
tissues
No specific cell
type
Cytoplasm Polypeptide hydrolysis
Nuclear Cell differentiation and
proliferation
Cis-trans isomerization
Plasma Hydrolysis of polypeptides via
POP (?) and ZIP (FAP) activity
Cell lines Neuronal Cytoplasm IP3 synthesis
Protein trafficking (?)
Non-neuronal Nuclear Cell proliferation
DNA synthesis (?)
Bacteria Hydrolysis of full length proteins
and polypeptides
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7 SUMMARY AND CONCLUSIONS
In this work, the distribution of POP was comprehensively studied in the brain and
peripheral tissues both in macroscopic and cellular level. Furthermore, the subcellular
localization of POP was determined and its spatial associations with specific neuronal
neurotransmitters (GABA, ACh and IP3) and its proposed substrate, SP, were examined.
The following conclusions can be drawn from the results of the present study:
1. POP protein was found in equally high amounts from the brain, testis, thymus and
kidney, and POP was distributed extensively in internal organs. Furthermore, POP
enzyme activities and relative protein amounts differed significantly, pointing to a strict
endogenous regulation of POP activity. At the cellular level, POP was present both in
the nuclei and cytoplasm of the peripheral tissues, suggesting a role in the cell cycle
and/or cell proliferation.
2.  POP was found to be widely but still specifically distributed in the main functional
areas in the human and rat brains. The locations of POP protein differed significantly
from the enzyme activity measurements and POP mRNA expression, pointing to some
kind of endogenous regulation of POP enzyme activity and post-translational
modification. Furthermore, the expression of POP in specific brain areas associated with
memory and learning and locomotor functions supports a role for POP in these
behaviors.
3. It was demonstrated that POP was present in GABAergic, cholinergic and
glutamatergic neurons in the brain, suggesting involvement both in excitatory and
inhibitory neurotransmission. Furthermore, localizations of POP in the cortex and the
corresponding projection areas in the thalamus are pointing to the involvement in the
thalamocortical neurotransmission. Subcellularly, POP was found in the cytosol, Golgi
apparatus and RER and to a minor extent in the myelin sheathed axons. These findings
suggest an involvement of POP in protein processing and the secretory functions of the
cells.
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4. POP was generally poorly colocalized with SP throughout the brain. This may
suggest a non-hydrolyzing role for POP and explains controversial results of POP
inhibitors on the neuropeptide levels in the brain. Moreover, practically no
colocalization between POP and the SP receptor, NK1R, was seen. Particularly
abundant colocalization of POP and IP3R1 in the hippocampus and thalamus points to a
role for POP in IP3 signalling and in memory and learning functions via the IP3-
mediated LTP.
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